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ABSTRACT 
Payers and providers face challenges in enabling appropriate and sustainable access to 
new medicines. To help enable rational use of new medicines various policy options 
exist. In Sweden, horizon scanning, forecasting, value-based pricing and 
reimbursement, treatment recommendations, and assessment of drug utilization 
patterns and patient outcomes in routine clinical practice have been used to facilitate 
rational introduction of new medicines. Such activities, however, should be informed 
by research and be subject to continuous evaluation. 
This thesis aims to examine selected elements of the process for managed introduction 
of new medicines. Study I provides an evaluation of the Swedish Horizon Scanning 
System. Study II assesses the impact of treatment recommendations on the use of new 
medicines in the specialized care setting. Finally, studies III and IV explore the utility 
of healthcare databases in the assessment of real-world use and outcomes of two 
specialist medicines prioritized for managed introduction. 
Different types of data were used in these studies, including public assessment reports 
published by the European Medicines Agency, early assessment reports prepared by 
the Swedish Horizon Scanning System, national sales data on all inpatient and 
outpatient medicines, regional administrative healthcare services data, and national 
registers of Statistics Sweden and the National Board of Health and Welfare.  
The evaluation of the Swedish Horizon Scanning System demonstrates that all 
innovative medicines that had substantial economic impact were identified and 
assessed prior to their introduction. The assessment of the impact of treatment 
recommendations shows that both local and regional treatment recommendations 
were associated with changes in the use of new medicines. Both regional and national 
healthcare databases provide the opportunity to study the use and outcomes of new 
medicines in routine clinical practice. 
The findings indicate that healthcare decision makers can rely on the outputs of the 
Swedish Horizon Scanning System to keep informed of new medicines. Moreover, 
treatment recommendations appear to influence the uptake and utilization of new 
specialist medicines. Finally, even though the existing Swedish data sources provide 
unique research opportunities, the assessment of appropriate use and relevant 
outcomes of the growing number of new specialist medicines may still be impeded by 
a lack of fit-for-purpose data. 
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1 INTRODUCTION 
This introductory chapter provides an overview of the development and approval of 
new medicines. This chapter also describes activities conducted by government 
agencies, payers, and providers that aim to facilitate access to new medicines and 
inform decision making around pricing, reimbursement, and formulary placement. 
1.1 DRUG DEVELOPMENT 
The introduction of a new medicine is a complex process spanning years and 
involving coordinated action of many stakeholders united by the common goal of 
improving patient outcomes. Drug development is filled with uncertainty and only few 
candidate molecules make it to the market and, of those that do, even fewer represent 
a significant breakthrough in medicine [1–5]. 
Transforming a candidate molecule to a pharmaceutical product requires extensive 
testing comprising nonclinical research and clinical trials [6]. Nonclinical research 
involves a variety of experiments to obtain information on safety (e.g. 
pharmacokinetics and toxicology studies) and efficacy (e.g. pharmacodynamics 
studies), as well as dosage, route, and frequency of administration [7–9]. When 
sufficient data from nonclinical studies have been obtained, permission to start clinical 
trials in humans is sought (approvals by both regulatory authorities and ethics 
committees are usually required) [10]. The aim of clinical trials is to examine the safety 
and efficacy of a candidate molecule in human volunteers. 
There are four phases of clinical trials. Phase I trials are the first studies of the 
candidate molecule in humans, with a focus on clinical pharmacology [10]. These 
studies assess safety, determine the dosage range, identify side effects, and detect early 
evidence of efficacy if the candidate molecule is studied in patients with disease [10–
12]. Phase II trials are exploratory efficacy studies that assess use for the targeted 
indication. These studies help determine dosage and inform the study design and 
selection of endpoints for use in subsequent clinical trials [6, 11, 13, 14]. Phase III 
trials are confirmatory studies designed to inform the benefit–risk assessment in 
support of marketing authorization [6]. Finally, Phase IV trials are conducted on 
marketed medicines to provide additional information on safety and efficacy [15]. 
To make a new medicine available to patients globally the pharmaceutical company 
must submit applications for product registration to regulatory authorities such as the 
European Medicines Agency (EMA) and the United States Food and Drug 
Administration (FDA). Marketing authorization is granted if the new medicine fulfills 
established quality, safety, and efficacy criteria and has a positive benefit–risk balance. 
Generally, Phase III trials are expected to have been completed at the time of 
submission of the marketing authorization application, but a new medicine can also be 
approved based on results from Phase II trials [16–20]. After approval, new research 
on the medicine can be initiated to study if it can be used for other indications, be 
administered via other administration routes, or be combined with other medicines. 
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Following regulatory approvals new medicines will be made available for use across 
markets. In line with the scope of this thesis the remainder of this chapter will cover 
key aspects related to the introduction of new medicines in Sweden. 
1.2 REGULATORY APPROVAL 
In Sweden, generally, there are four distinct registration pathways available for 
applying for marketing authorization: national procedure, mutual recognition 
procedure, decentralized procedure, and centralized procedure [21]. A brief summary 
of these is provided below. Detailed and up-to-date information can be found on the 
websites of EMA and the Swedish Medical Products Agency [21, 22]. 
If a medicine is intended for marketing only in Sweden, the pharmaceutical company 
can submit a marketing authorization application to the Swedish Medical Products 
Agency (the national procedure) [21]. The mutual recognition procedure allows the 
marketing authorization granted in one member state to be recognized in other 
European Union countries. In the decentralized procedure, a medicine that has not yet 
been authorized in the European Union can be authorized in more than one member 
state in parallel. In practice, the national, mutual recognition, and decentralized 
procedures are seldom used when marketing authorization is sought for a new 
innovative medicine. 
The centralized procedure allows pharmaceutical companies to submit a single 
marketing authorization application to EMA. If authorized, the medicine can be 
marketed throughout the European Union [22]. The centralized authorization 
procedure is compulsory for new medicines with specific therapeutic indications 
(human immunodeficiency virus or acquired immune deficiency syndrome, cancer, 
diabetes, neurodegenerative diseases, auto-immune and other immune diseases, viral 
diseases). Moreover, biotechnology-derived medicines, advanced therapy medicines, 
and orphan medicines must also be authorized through the centralized procedure. The 
procedure may also be used if the applicant can show that the medicinal product 
constitutes an important therapeutic, scientific, or technological innovation. For a 
submitted marketing authorization application, EMA publishes either a European 
public assessment report that describes the scientific basis for its recommendation or, 
if the application was withdrawn, the withdrawal letter together with a withdrawal 
assessment report. 
Regulatory agencies, including EMA, have aimed at fostering development of 
medicines with the potential to address unmet medical needs and at facilitating faster 
access for patients to innovative medicines [22–25]. Existing regulatory tools include 
scientific advice, accelerated assessment, conditional marketing authorization (approval 
based on limited clinical data with provision of comprehensive data within an agreed 
timeframe), and compassionate use (use of unauthorized medicines outside the clinical 
study setting). Recent initiatives include the launch of the priority medicines scheme 
based on enhanced interaction and early dialogue with developers of promising 
medicines in order to optimize development plans and speed up evaluation [22]. 
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1.3 PRICING AND REIMBURSEMENT 
On the path toward commercialization of a new medicine, the demonstration of a 
positive benefit–risk balance is only one step. Increasingly, pharmaceutical companies 
also have to demonstrate value for money to ensure reimbursement by payers. 
Sweden has a national healthcare system that is primarily funded through direct 
taxation [26, 27]. Health policy is governed at the national level, while regions are 
largely responsible for decision making and provision of healthcare services. The 
Dental and Pharmaceutical Benefits Agency (TLV)—a national government agency—
is responsible for value-based pricing and reimbursement of outpatient prescription 
medicines [28]. Medicines used in hospitals are not covered by the national 
reimbursement scheme. While the TLV can be asked to assess the cost-effectiveness 
of some new medicines intended for hospital use, the procurement of all inpatient 
medicines is managed by the regions.  
For an outpatient medicine to be reimbursed and included in the national 
pharmaceutical benefits scheme the pharmaceutical company needs to submit an 
application to the TLV [28]. In the application the company states the price applied 
for and provides supporting clinical and health economic documentation. The 
decision of the TLV is based on a number of factors, including three fundamental 
principles—human value, need and solidarity, and cost-effectiveness—that guide 
priority setting in the healthcare system (the Health and Medical Services Act [SFS 
2017:30]). Provided that the first two guiding principles are fulfilled, reimbursement is 
granted if the TLV finds that the requested price is justified in relation to the value the 
new medicine brings. This value-based approach to pricing and reimbursement aims 
to provide access to cost-effective and innovative medicines and to ensure cost-
effective use throughout the product’s lifecycle. 
There are two main types of reimbursement that the TLV may grant [28]. General 
reimbursement means that a medicine is eligible for reimbursement for its entire 
approved indication. Reimbursement may also be restricted to a certain area of use or 
a subgroup of patients. Additionally, conditions for reimbursement may apply, such as 
the requirement that the pharmaceutical company provides follow-up data on the use 
and outcomes of the approved medicine. Also, within the framework of the pricing 
and reimbursement scheme, a pharmaceutical company and the regions may enter into 
an agreement that in turn impacts the decision by the TLV. In practice, such a 
managed entry agreement can mean that the list price set by the TLV does not apply 
(e.g. by way of a price discount or risk sharing arrangement). 
Detailed and up-to-date information on the pricing and reimbursement of medicines 
in Sweden can be found on the TLV website [28]. Moreover, a comprehensive 
overview of the Swedish healthcare system with focus on pricing and reimbursement 
of medicinal products has recently been published [29]. 
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1.4 FINANCING OF NEW MEDICINES 
While the TLV decides on which medicines are included in the national 
pharmaceutical reimbursement scheme, the agency does not hold budget 
responsibility. As mentioned earlier, the regions are largely responsible for decision 
making and provision of healthcare services, including financing of outpatient and 
inpatient medicines. Healthcare services are financed by local taxes and supplemented 
by central government grants and patient copayments [26]. 
Costs of inpatient medicines are covered in full by the regions. For reimbursed 
outpatient medicines the regions receive a designated government grant and patients 
are charged a copayment (up to SEK 2300 for a rolling 12-month period). Patients pay 
the full amount for prescription medicines that are not included in the reimbursement 
scheme as well as for over-the-counter medicines [28]. 
 
Figure 1. National sales of medicines (excluding over-the-counter medicines) 
In Sweden, annual sales of inpatient and prescribed outpatient medicines amount to 
almost SEK 40 billion, of which SEK 30 billion is for prescribed outpatient medicines 
(Figure 1). The introduction of new medicines for the treatment of hepatitis C and 
cancer as well as the growing use of some older products, such as non-vitamin K 
antagonist oral anticoagulants, have contributed to the increase in pharmaceutical 
expenditure seen in recent years. 
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Source: Swedish eHealth Agency (annual data)
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1.5 CHALLENGES PAYERS FACE IN ENABLING ACCESS TO 
NEW MEDICINES 
The value that new innovative medicines bring is well recognized and efforts are made 
to encourage pharmaceutical innovation to address unmet needs [22, 30]. However, 
not all new medicines are breakthroughs, yet many come with a price premium, and it 
is not always easy to discern the value at the time of introduction. This is particularly 
true for medicines approved based on limited data [31, 32]. Even if an extensive 
clinical development program has been completed, at the time of introduction there is 
always uncertainty about real-world effectiveness, safety, and economic impact. 
Moreover, as the number of treatment options in a given therapeutic area increases it 
can become more difficult for patients and clinicians to select the most optimal 
treatment. Comparative effectiveness and safety data—not only in relation to the 
established standard of care but also among recently introduced treatment options—
are thus needed to inform decision making. Finally, even if a new medicine is indeed a 
breakthrough, the question of affordability inevitably comes up [33–36]. 
It is acknowledged that payers face various challenges in enabling rational use of new 
medicines [37–41] and the subject of access has increasingly been discussed in recent 
years [42–45]. The past decades have seen a rapid increase in the number of new 
specialist medicines, including novel approaches to treat cancer and rare diseases as 
well as cures such as new medicines for hepatitis C, that address previously unmet 
needs. In parallel with scientific advances that fuel the research and development 
pipeline, patients are also changing. Patients are becoming more informed, engaged, 
and empowered and healthcare systems are moving toward person-centered care [46–
48]. Also, demographic changes are contributing to the growing burden of chronic 
diseases [49, 50]. These parallel developments, however, unfold in the reality of 
constrained healthcare budgets. 
1.6 EVOLUTION OF THE MANAGED INTRODUCTION OF NEW 
MEDICINES IN SWEDEN 
In 2005, following years of rapid growth in pharmaceutical expenditure, an initiative 
was launched by the drug and therapeutics committee in Region Stockholm with the 
aim to develop an effective model for the introduction of new medicines [37, 51]. In 
addition to the growing budget impact, uncertainty around patient outcomes was a key 
driver of the initiative [37]. The focus was on specialist medicines and medicines 
intended for use in large patient populations [51]. The resulting model comprised a 
number of activities, including horizon scanning and forecasting with the aim to 
inform and allow healthcare providers and administrators to prepare for the 
introduction of new medicines. For selected medicines, regulatory data and published 
clinical trials were used to assess the clinical value in relation to established treatment 
options. For medicines evaluated by the TLV, potential health economic 
consequences were also assessed. For medicines selected for managed introduction, 
treatment recommendations were developed and requirements for the assessment of 
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use and outcomes in routine clinical practice were defined. This model for managed 
introduction and rational use of new medicines was facilitated by the involvement of 
medical experts and prescribers. Furthermore, various communication tools and 
educational efforts were used to facilitate the rational use of new medicines. In 2008, a 
comprehensive description of the model was published in the Swedish medical journal 
Läkartidningen [51]. 
The regional model described above served as the foundation upon which further 
processes for managed introduction and assessment of new medicines were developed 
[39, 52, 53]. As part of the National Pharmaceutical Strategy introduced in 2011, the 
Swedish Association of Local Authorities and Regions established a national 
collaboration to promote effective, safe, and equitable use of new medicines [54]. This 
collaboration has brought together the regions, drug and therapeutics committees, 
government agencies, and pharmaceutical companies. An up-to-date description of the 
national model can be found on a dedicated website [55]. 
1.7 HORIZON SCANNING 
As mentioned earlier, horizon scanning was included as a step in the Stockholm model 
to support planning and to optimize the readiness of the healthcare system for the 
introduction of new medicines [51, 53]. Horizon scanning can be defined as the 
“systematic identification of health technologies that are new, emerging, or becoming 
obsolete and that have the potential to effect health, health services, and society” [56]. 
An in-depth description of the evolution and current status of horizon scanning in 
Sweden was published as part of this thesis project (see Appendix). 
Over the years, horizon scanning has become a key early health technology assessment 
tool [42]. In light of this, it is becoming increasingly important to critically assess 
horizon scanning outputs. In Sweden, both regional and national decision makers rely 
on the Swedish Horizon Scanning System to keep informed and prepare for the 
introduction of new medicines [53]. The prioritization by the Horizon Scanning 
Working Group may, for example, inform the priority setting at the regional level. 
Moreover, at the national level, it can influence the decision to include a medicine in 
the national process for managed introduction [55]. Therefore, it is critical that 
prioritization decisions are made judiciously and are as accurate as possible. 
1.8 TREATMENT RECOMMENDATIONS 
Treatment guidelines and recommendations—that can be defined as “systematically 
developed statements to assist practitioner and patient decisions about appropriate 
healthcare for specific clinical circumstances” [57]—have the potential to improve 
quality of care, optimize patient outcomes, and reduce costs by focusing resources on 
the most effective treatment options [58]. Additionally, they can serve as a foundation 
for performance measures, appropriate use criteria, and clinical decision support tools. 
For decades, various stakeholders, including government agencies, physician 
organizations, academic and independent research centers, payers, and hospitals, have 
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issued treatment guidelines and recommendations to facilitate the rational use of 
medicines. 
In Sweden, recommendations on the use of medicines have been primarily developed 
by drug and therapeutics committees. The first drug and therapeutics committee was 
established in 1961 at the Karolinska University Hospital in Stockholm with the aim to 
evaluate new and established medicines and define the hospital formulary [59]. Over 
the years similar functions were established across Sweden and in 1997 it became 
mandatory for each region to operate a regional drug and therapeutics committee [60, 
61]. This was followed by the devolution of responsibility for the financing of 
medicines from the state to the regions [62]. 
The aim of the regional drug and therapeutics committees is to develop locally 
relevant treatment recommendations and formularies to support both general 
practitioners and specialists [52]. The work is organized around expert groups on 
therapeutic areas. As an example, the drug and therapeutics committee in Region 
Stockholm aims to operate a transparent process for developing recommendations, 
which involves experts and clinicians (using strict criteria for handling potential 
conflicts of interest), prescribing feedback and decision support, continuous medical 
education, and a model that links financial incentives to the level of adherence to the 
recommendations [63]. The committee manages an essential medicines formulary (the 
Wise List) that has successfully been used to influence prescribing behavior [63–68]. 
Additionally, a number of Swedish government agencies are involved in supporting 
healthcare decision makers. For example, the National Board of Health and Welfare 
issues national guidelines to support decisions concerning patient care and the 
allocation of resources within healthcare and social services [69]. Also, as part of the 
national process for managed introduction of new medicines, the New Therapies 
Council issues recommendations on the use of new medicines with the aim to enable 
effective, safe, and equitable treatment of patients across regions [53, 70]. 
1.9 REAL-WORLD DATA AND REAL-WORLD EVIDENCE 
Over the past decades, observational research has provided evidence on the use, 
benefits, and harms of medicines [71]. Substantial methodological advances have been 
made and greater knowledge of the potential and limitations of various types of data 
has been acquired. Technological developments have enabled collection of 
unprecedented amounts of data as part of healthcare provision. The terminology used 
has also evolved with the terms “real-world data” and “real-world evidence” rapidly 
becoming dominant (Figure 2). 
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Figure 2. Number of hits for "real-world data" and "real-world evidence" 
Multiple definitions of “real-world data” (RWD) and “real-world evidence” (RWE) 
have been proposed [72, 73]. The United States FDA—in a report outlining the 
agency’s planned framework for use of RWE to support regulatory decisions—
provides the following definitions [74]: “[RWD] are data relating to patient health 
status and/or the delivery of health care routinely collected from a variety of sources” 
and “[RWE] is the clinical evidence about the usage and potential benefits or risks of a 
medical product derived from analysis of RWD.” 
While many have defined RWD as data collected in non-randomized controlled trial 
settings [73], others stress that “real-world research and the concepts of a planned 
intervention and randomization are entirely compatible” [72]. The term RWE can thus 
apply to a broad range of research that encompasses both observational studies and 
studies that incorporate planned interventions regardless of whether treatment is 
allocated through randomization or not. In view of this, RWE is evidence that is 
derived from analyses of data from multiple sources outside conventional clinical 
research settings [72]. 
Sources of RWD include electronic health records, administrative healthcare data, 
patient registries, and patient-generated data. A thorough description of commonly 
used RWD sources, including related topics such as data quality and record linkage can 
be found elsewhere [75]. Sweden has a considerable number of administrative and 
medical registers that cover the entire population [76]. These registers provide unique 
possibilities for research as they allow for continuous follow-up and individual-level 
0
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Source: ncbi.nlm.nih.gov/pubmed (annual data)
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linkage of records between national socioeconomic registers, up-to-date death records, 
data generated within the healthcare system, biobanks, and population-based surveys. 
RWE has become a multidisciplinary field that brings together the established 
disciplines of drug utilization research, health economics and outcomes research, and 
pharmacoepidemiology [77]. The ultimate goal of RWE generation is to support 
decision making by stakeholders in the healthcare system. Use cases include regulatory 
approval [78–81], pricing and reimbursement [82–84], formulary decisions [85–88], as 
well as continued benefit–risk assessment of marketed medicines [89, 90]. 
However, the evaluation of medicines outside of controlled clinical research settings is 
fraught with methodological challenges [91]. Concerns have also been raised that there 
is shortage of qualified researchers and that current educational efforts are inadequate 
[92]. These concerns are further compounded by the growing availability of user-
friendly analytics tools that inadvertently may lead to an increased number of poorly 
designed and executed studies [72]. Nonetheless, well-executed and timely analyses can 
play an important role in healthcare decision making. 
 

  11 
2 AIMS 
This thesis aims to examine the process for managed introduction of new medicines in 
Sweden. Study I provides an evaluation of the Swedish Horizon Scanning System. 
Study II assesses the impact of treatment recommendations on the use of new 
medicines in the specialized care setting. Studies III and IV explore the utility of 
healthcare databases in the assessment of real-world use and outcomes of two 
specialist medicines prioritized for managed introduction. The objectives of the four 
studies of this thesis are presented below. 
Study I To assess whether the Swedish Horizon Scanning System identified and 
accurately prioritized new medicines. 
Study II To assess the impact of treatment recommendations on the utilization of 
disease-modifying treatments in relapsing-remitting multiple sclerosis. 
Study III To describe patients initiating dimethyl fumarate and measure treatment 
persistence in treatment-naïve patients and in patients switching to 
dimethyl fumarate from other disease-modifying treatments. 
Study IV To describe the use of olaparib and measure time to treatment 
discontinuation and overall survival in patients treated during the first three 
years following regulatory approval. 
 

  13 
3 METHODS 
This chapter provides an overview of data sources, study designs, and statistical 
analyses used in the four studies that form the basis for this thesis. Table 1 presents an 
overview of the studies. The chapter concludes with a discussion around ethical issues 
that were considered during the course of the research. 
Table 1. Overview of the studies that form the basis for this thesis 
 Description Design Data sources Study 
period 
Study I Evaluation of the Swedish 
Horizon Scanning System 
(Early Awareness and 
Alert System) 
Diagnostic 
accuracy 
study 
European Medicines Agency: 
European public assessment 
reports; data on withdrawals 
of initial marketing 
authorization applications 
Swedish eHealth Agency: 
national sales data 
Horizon Scanning 
Working Group: 
early assessment reports 
2010–
2017 
Study II Assessment of the impact 
of both the introduction of 
new medicines and 
treatment 
recommendations on 
multiple sclerosis drug 
utilization  
Interrupted 
time series 
study 
Region Stockholm: 
administrative healthcare 
services data 
2011–
2017 
Study III Description of patients 
treated with dimethyl 
fumarate and assessment 
of treatment outcomes 
using regional data 
Cohort 
study 
Region Stockholm: 
administrative healthcare 
services data 
2010–
2017 
Study IV Description of patients 
treated with olaparib and 
assessment of treatment 
outcomes using national 
data 
Cohort 
study 
Statistics Sweden: 
Total Population Register 
National Board of Health 
and Welfare: 
National Patient Register; 
Prescribed Drug Register; 
Cancer Register; Causes of 
Death Register 
Swedish eHealth Agency: 
national sales data 
2005–
2017 
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3.1 DATA SOURCES 
This section provides an overview of the data sources used in the studies. 
Study I 
Data for the study on the Swedish Horizon Scanning System were collected from 
EMA, the Swedish eHealth Agency, and the Horizon Scanning Working Group. 
First, public information on initial marketing authorization applications was obtained 
from EMA for all medicinal products processed between 1 January 2010 and 31 
December 2015. All European public assessment reports on medicines and all 
withdrawals of initial marketing authorization applications were compiled.  
Second, national aggregate monthly sales data for all new medicines were obtained 
from the Swedish eHealth Agency. This is an agency tasked to lead and coordinate 
national government eHealth initiatives [93]. As part of its remit, the agency maintains 
national records of all pharmaceutical sales by pharmacies, retailers, and wholesalers—
covering both hospital sales and medicines dispensed in outpatient care. For each 
transaction, information is captured on the medicinal product’s formulation, strength, 
and pack size, as well as price and the date of sale.  
Finally, all medicines prioritized by the Swedish Horizon Scanning System were 
identified and all early assessment reports were retrieved from the Horizon Scanning 
Working Group. 
Studies II and III 
The two studies on regional drug utilization and treatment outcomes in multiple 
sclerosis used data derived from the VAL data warehouse owned and operated by 
Region Stockholm [94]. One of the key responsibilities of Region Stockholm is the 
provision of healthcare to all residents of the region. The VAL data warehouse 
contains data on all provided healthcare services. Region Stockholm—with 12.5 
million primary care visits, 5.5 million outpatient specialist visits, and 260,000 hospital 
admissions in 2018 [95]—is one of the largest healthcare providers in Europe [96]. 
In an international context, the VAL data warehouse is unique in providing years of 
longitudinal data that facilitate comprehensive follow-up capabilities of all care 
encounters that patients have across the entire healthcare system [97]. Consequently, 
the VAL data are of value for resource planning as well as quality and effectiveness 
evaluations of healthcare providers. The content of the VAL data warehouse 
databases ranges from detailed information on primary care visits and dispensed 
medicines to migration dates to and from the region. All healthcare providers that are 
contracted by Region Stockholm regularly submit information and the databases are 
generally updated on a monthly basis. 
All data on patient care encounters—inpatient, outpatient specialist, and primary 
care—were retrieved from databases that contain information on providers, diagnoses, 
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and procedures. Outpatient drug utilization records were obtained from the pharmacy 
dispensing database. Hospital-administered medicines were derived using procedure 
codes recorded during hospitalizations and outpatient specialist care visits. Patient 
characteristics, migration dates, and mortality data were also obtained. 
Study IV 
The national study on olaparib was conducted using data from the Swedish 
population-based registers. These registers are managed by Statistics Sweden and the 
National Board of Health and Welfare. 
Statistics Sweden is a government agency responsible for developing, producing, and 
disseminating official statistics [98]. The agency maintains a number of registers and 
databases that are often used in research, such as the Total Population Register that 
provides the foundation for the nation’s population and household statistics [99]. 
Examples of information recorded in this register include sex, age, marital status, 
migration, births, deaths, marriages, and divorces. 
The National Board of Health and Welfare is a government agency under the Ministry 
of Health and Social Affairs with a number of responsibilities related to health and 
social care, including the development of national care support programs, the 
development of regulations and guidelines, and the evaluation of quality and 
effectiveness of healthcare providers [69]. As a part of its remit, the National Board of 
Health and Welfare develops and maintains a number of nation-wide registers that 
cover health data and social services.  
For the study, individual-level register data were provided by the agencies described 
above. Deterministic linkage between records [100] was facilitated by matching on the 
personal identity number, which is assigned to all Swedish residents. 
Medical information was obtained from the National Patient Register, which contains 
all inpatient care and outpatient visits, in addition to day surgery and psychiatric care 
from both private and public healthcare providers in Sweden [69]. Broadly, the register 
contains four types of data: patient data (e.g. sex, age, and place of residence), 
healthcare provider data, administrative data (e.g. date of stay and type of care), and 
medical data in terms of recorded diagnoses and procedures.  
The Prescribed Drug Register provided data on all dispensed prescription medicines in 
ambulatory care [101]. This register contains records of all medicines dispensed in 
outpatient pharmacies with details on the patient and the prescriber, the medicine 
name, anatomical therapeutic chemical classification system (ATC) code, strength and 
pack size, prescribing and dispensation dates, and costs (reimbursed expenditure and 
patient copayment). 
Healthcare providers in Sweden are mandated to report newly detected cancer cases to 
the Swedish Cancer Register [102]. Each new cancer case—whether diagnosed 
through clinical, morphological, or laboratory findings, including cases diagnosed at 
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autopsy—generates a report. Recorded medical data include site of tumor, histological 
type, and stage. For this study, information was obtained on the primary site of the 
tumor, its malignancy, histology, stage, and the date of diagnosis.  
In addition, mortality data were derived from the Causes of Death Register, which is 
the source of official mortality data in Sweden [103].  
Finally, the Swedish eHealth Agency provided aggregate monthly sales data that were 
used to estimate use of medicines not captured at the individual level, such as 
medicines administered in the hospital setting [93]. 
3.2 STUDY DESIGNS 
This section describes the diagnostic accuracy, interrupted time series, and cohort 
study designs used in this thesis. 
Study I 
Methodology commonly used in diagnostic accuracy studies was used to evaluate the 
Swedish Horizon Scanning System. In the assessment of the discriminative power of a 
test, the index test’s classification of a target condition is compared with the 
classification of a reference standard [104, 105]. In the context of this study, the 
prioritization made by the Swedish Horizon Scanning System comprised the index 
test, while national sales data served as the reference standard (Figure 3). 
 
Figure 3. Contingency table describing the relationship between results of the index test and 
the reference standard 
Reference standard 
National sales*
Index test 
HS System
Prioritized
Not 
prioritized
> €4 million ≤ €4 million
True positive False positive
False negative True negative
HS horizon scanning

* In the second year on the market
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All initial marketing authorization applications for medicinal products processed by 
EMA between 1 January 2010 and 31 December 2015 comprised the study population 
and were classified using the index test and the reference standard. Sensitivity was 
defined as the proportion of prioritized medicines among all medicines exceeding the 
sales threshold (€4 million). Specificity was defined as the proportion of non-
prioritized medicines among all medicines below the sales threshold. Positive 
predictive value was defined as the proportion of medicines exceeding the sales 
threshold among all prioritized medicines. Negative predictive value was defined as 
the proportion of medicines below the threshold among all non-prioritized medicines. 
Study II 
An interrupted time series design was used to assess the impact of treatment 
recommendations [106]. The outcome of interest was the number of users of each 
disease-modifying treatment before and after different types of interventions that were 
hypothesized to have had an impact on drug utilization. The study design is 
summarized in Figure 4. 
 
Figure 4. Visualization of the interrupted time series study design 
A population-based study of all Region Stockholm residents diagnosed with multiple 
sclerosis and treated with disease-modifying treatments was conducted. All patients 
with at least one diagnosis of multiple sclerosis and at least one dispensation or 
administration of a disease-modifying treatment from 1 January 2011 to 31 December 
2017 comprised the study population. 
Figure 5 depicts the introduction of new medicinal products and the dissemination of 
new treatment recommendations—referred to as interventions—that may have 
influenced the utilization of disease-modifying treatments in Region Stockholm. 
Ou
tc
om
e
Time
Eﬀect of 
intervention
A time series of the outcome is used to establish a trend. Following the intervention, the 
outcome variable is observed for an immediate eﬀect and a change in the trend compared 
to the predicted values. The time point of the intervention is indicated by the vertical bar.
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Figure 5. Interventions that may have influenced the utilization of disease-modifying treatments 
in multiple sclerosis 
Study III 
A population-based cohort study was conducted to assess all Region Stockholm 
residents who initiated treatment with dimethyl fumarate (Tecfidera) from its 
regulatory approval until 31 May 2017. A graphical depiction of the study design is 
provided in Figure 6. Dimethyl fumarate persistence was defined as the number of 
days from the cohort entry date until either discontinuation or switching to another 
disease-modifying treatment. 
2011
2012
2014
2016
2013
2015
2017
2018
fingolimod 
Reimbursement

August 2011
dimethyl fumarate 
DTC recommendation (regional) 

October 2015
rituximab 
Local recommendation

(largest multiple sclerosis clinic)

November 2012
alemtuzumab  
Marketing authorization

September 2013
dimethyl fumarate 
Reimbursement

May 2014
teriflunomide 
Reimbursement

June 2014
peginterferon beta-1a 
Reimbursement

May 2015
daclizumab 
Reimbursement

February 2017
DTC drug and therapeutics committee
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Figure 6. Cohort study schematic (Study III) 
Study IV 
A population-based cohort study was conducted to assess all residents of Sweden who 
initiated treatment with olaparib (Lynparza) from its regulatory approval until 31 
December 2017. A graphical depiction of the study design is provided in Figure 7. 
Time to olaparib discontinuation was defined as time from the cohort entry date to 
the end of supply of dispensed olaparib or death. Overall survival was defined as time 
from the cohort entry date to the date of death from any cause. 
 
Figure 7. Cohort study schematic (Study IV) 
3.3 STATISTICAL ANALYSES 
Baseline characteristics of study populations were presented using descriptive statistics. 
Categorical data were described using frequencies and proportions. For continuous 
data, means or medians were presented together with standard deviations or ranges. 
Outcomes

• persistence with 
dimethyl fumarate
Cohort entry date

First dispensation of dimethyl fumarate*
End of 
data
Start of 
data
2010

Jul 1
2017

May 31
Patient assessment

• demographic data

• history of relapses

• comorbidities

• healthcare resource utilization

• treatment patterns
Baseline period Follow-up period
The baseline period spans the 12 months preceding the cohort entry date.

Follow-up starts on the cohort entry date and continues until the earliest of 
emigration, death, or end of the study period.

*Since regulatory approval

Cohort entry date

First dispensation of olaparib*
End of 
data
Start of  
data
2005

Jan 1
2017

Dec 31
Outcomes

• olaparib discontinuation

• overall survival
Patient assessment

• demographic data

• cancer diagnosis

• tumor location and characteristics

• personal and family history
Baseline period Follow-up period
The baseline period includes all available data preceding the cohort entry date.

Follow-up starts on the cohort entry date and continues until the earliest of 
emigration, death, or end of the study period.

*Since regulatory approval
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Study I 
The accuracy of the prioritization of the Swedish Horizon Scanning System was 
summarized in a contingency table. Outcome statistics were reported as sensitivity, 
specificity, positive predictive value, and negative predictive value with 95% Clopper–
Pearson binomial confidence intervals [107, 108]. 
Study II 
To determine whether the identified interventions could have had the potential to 
influence utilization patterns of disease-modifying treatments, the number of monthly 
prevalent users of each medicine was plotted. A linear regression model was fitted 
over each time series for visual inspection of time trends. With the Durbin–Watson 
statistic, data were tested for first-order autocorrelation and, if present, corrected for 
this with an autoregressive term in the model [109, 110].  
A segmented regression model with a step function was used to perform the 
interrupted time series analysis [106, 111]. Two different outcomes—the step change 
(immediate effect) and the change in slope (trend)—were both compared to the 
predicted values. Pre- and post-intervention timeframes were chosen so that none of 
the other interventions overlapped with these time periods. When the step change 
clearly lasted longer than one month, the model was shaped to this. 
Studies III and IV 
The main treatment-related outcomes were treatment persistence (Study III) and time 
to discontinuation and overall survival (Study IV). These time-to-event endpoints were 
analyzed by deriving nonparametric estimates of the survivor functions [112].  
In all analyses, the duration variable for each subject was defined as the time from 
treatment initiation (cohort entry date) to the outcome of interest (event), loss to 
follow-up, or end of study, whichever came first. Subjects who did not have the event 
of interest during the follow-up period were censored. The Kaplan–Meier product-
limit method was used to derive survival estimates and to plot the survivor function. 
Statistical software 
Data management and analyses in Study I were conducted using Stata 14.2 (College 
Station, TX, United States). For Study II, data management was conducted using SAS 
9.4 (Cary, NC, United States) and analyses were conducted using Stata 14.2 and IBM 
SPSS Statistics 24.0 (Armonk, NY, United States). Data management and analyses in 
studies III and IV were conducted using SAS 9.4.  
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3.4 ETHICAL CONSIDERATIONS 
A number of ethical issues were considered for the studies of this thesis.  
Publicly available data related to marketing authorization applications submitted to 
EMA as well as aggregate-level national sales data were used in Study I. This research 
did not involve humans and was therefore exempt from ethics review requirements. 
Studies II, III, and IV, however, were observational studies based on individual-level 
data. Because such data contain sensitive personal information, ethics committee 
review was required [113]. In Sweden during the conduct of these studies a number of 
regulations governed ethical vetting of research that involves humans (the Ethical 
Review Act [SFS 2003: 460] and the statutes SFS 2003:615, SFS 2007:1069, and SFS 
2007:1068). Information on ethics approvals obtained for this thesis is provided in 
Table 2. 
Table 2. Ethics approvals obtained for each study 
 Application 
type 
Title Date of 
decision 
Reference 
Studies II 
and III 
Original 
submission 
Assessment of new medicines 
for treatment of multiple 
sclerosis: a database study 
[Uppföljning av nya läkemedel 
för behandling av multipel 
skleros: en registerstudie] 
2016-02-17 2015/2329-
31/4 
Study IV Original 
submission 
Assessment of drug utilization in 
cancer care in the Stockholm–
Gotland healthcare region 
[Registrering och uppföljning av 
läkemedelsbehandling inom 
cancervården i hälso- och 
sjukvårdsregionen Stockholm–
Gotland] 
2012-09-06 2012/1236-
31/4 
 Amendment  2012-10-29 2012/1726-32 
 Amendment  2015-10-20 2015/1790-32 
Specific items in the application for ethics approval that are relevant and important to 
observational research include privacy and confidentiality of data, security of data, 
informed consent, and risks and benefits of the research project. 
Privacy refers to the right of individuals to keep information about themselves from 
being disclosed to others and to be free from surveillance or interference from other 
individuals, organizations, or the government [114]. Confidentiality addresses the issue 
of how personal data that have been collected may be held and used by the 
organization that collected the data, what other secondary uses may be made of the 
data, and when the permission of the individual is required for such uses [115]. 
Security can be defined as the procedural and technical measures required to prevent 
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unauthorized access, modification, use, and dissemination of data stored or processed 
in a computer system, to prevent any deliberate denial of service, and to protect the 
system in its entirety from physical harm [116]. 
Centralized de-identification of data provided protection of privacy and confidentiality 
within this research project. Region Stockholm performs de-identification before data 
are released to the VAL data warehouse. Similarly, Statistics Sweden and the National 
Board of Health and Welfare process national individual-level data before delivery to 
researchers. Moreover, the researchers themselves are bound by regulations and moral 
responsibility to use data only for purposes of the approved research.  
De-identification also entails that researchers do not know who the research subjects 
are, which makes it impossible to seek informed consent from these individuals. The 
lack of informed consent can be viewed as an issue. However, the observational 
studies conducted within this research project had no impact on the care provided to 
patients, nor did the research require any contact with the study subjects. There is 
generally, both in Sweden and internationally, no requirement for informed consent 
when using only de-identified data from administrative databases. Moreover, seeking 
informed consent may even hamper research and make addressing objectives of 
observational studies unattainable [117]. 
In terms of data security, the environment in which research was conducted was 
tightly controlled. Access to data was restricted to authorized researchers only. 
Additionally, security of data was protected through procedural and technical 
measures including, but not limited to, firewalls, encryption, password access, and 
monitoring of users. 
Finally, risks and benefits of the research project should also be discussed. The 
primary concern is the unlikely, but nonetheless possible, risk of breaching privacy and 
confidentiality of individuals included in research. It must be acknowledged that even 
the most elaborately de-identified datasets may retain identifiable information and 
concerns over current de-identification standards have been expressed [75]. In fact, 
the possibility to re-identify individuals from de-identified data has been demonstrated 
and it may be that it is no longer possible to create truly de-identified or anonymized 
datasets. Legislation, professional standards, and moral responsibility are thus of key 
importance and it is expected that regulations will continue to evolve in order to 
guarantee that released data are used strictly for the approved research. 
For the studies of this thesis, routinely collected individual-level data can be 
considered the best source of information to address the study objectives. The 
research provided important information on the uptake and use of new medicines 
among all patients, including description of patient characteristics that can highlight 
possible gaps and unmet medical needs. The dissemination of information on patient 
outcomes in routine clinical practice can help patients, clinicians, payers, and policy 
makers to make informed decisions around the use of new medicines. 
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4 RESULTS 
This chapter provides a summary of the results. For each study, the study population 
is described followed by key findings. 
4.1 STUDY I 
The output generated by the Swedish Horizon Scanning System, since its inception 
until the end of 2015, as well as sales of all new medicines introduced on the Swedish 
market were assessed. 
From 2010 to the end of 2015, EMA published 462 European public assessment 
reports on medicinal products that were either granted or refused marketing 
authorization. During the same time period, the initial marketing authorization 
applications for 64 additional medicinal products were withdrawn by the 
pharmaceutical companies. After applying the study selection criteria—primarily 
resulting in the exclusion of generics or known active substances for use in an already 
approved indication—253 medicinal products remained in the study population. 
During the same time period, the Swedish Horizon Scanning System published early 
assessment reports for 104 new medicines. Following the exclusion of 33 reports—
most frequently for covering extensions of indications—71 prioritized medicines 
remained (positive index test). Figure 8 provides information on the study population 
and the prioritized medicines. 
Table 3 lists all 71 prioritized medicines. Of these, 16 products were classified as 
having substantial economic impact on the healthcare system. An additional five 
medicinal products also had substantial sales but were not prioritized by the Swedish 
Horizon Scanning System (Table 4). 
Among the prioritized medicines, 55 were classified as not having substantial 
economic impact. Seven of these medicines were not granted marketing authorization. 
An additional six medicines were authorized but had no sales in the first two years on 
the market (naltrexone/bupropion [Mysimba], teduglutide [Revestive], afamelanotide 
[Scenesse], telaprevir [Incivo], boceprevir [Victrelis], radium Ra223 dichloride 
[Xofigo]). There were, however, three cancer medicines with sales nearly reaching the 
sales threshold (pertuzumab [Perjeta], dabrafenib [Tafinlar], and trastuzumab 
emtansine [Kadcyla]). 
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Figure 8. Description of new medicines comprising the study population 
All medicines 
Processed by EMA: 253
Prioritized medicines 
Selected by the HS System: 71
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New active substances86% 93%
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Table 3. Medicines prioritized by the Swedish Horizon Scanning System 
Medicinal 
product 
ATC code Common name EMA date* Prioritization 
date# 
Constella A06AX04 linaclotide 2012-11-26 2012-03-29 
Belviq A08AA11 lorcaserin w2013-05-03 2012-12-13 
Mysimba A08AA62 naltrexone/bupropion 2015-03-26 2015-01-07 
Saxenda A10BJ02 liraglutide 2015-03-23 2014-11-06 
Forxiga A10BK01 dapagliflozin 2012-11-12 2012-02-01 
Revestive A16AX08 teduglutide 2012-08-30 2012-04-13 
Brilique B01AC24 ticagrelor 2010-12-03 2010-06-01 
Eliquis B01AF02 apixaban 2011-05-18 2011-06-07 
Brinavess C01BG11 vernakalant hydrochloride 2010-09-01 2010-11-29 
Intuniv C02AC02 guanfacine 2015-09-17 2015-03-09 
Adempas C02KX05 riociguat 2014-03-27 2014-02-13 
Entresto C09DX04 sacubitril/valsartan 2015-11-19 2015-09-30 
Repatha C10AX13 evolocumab 2015-07-17 2015-05-11 
Scenesse D02BB02 afamelanotide 2014-12-22 2012-02-15 
Betmiga§ G04BD12 mirabegron 2012-12-20 2012-08-24 
Olysio J05AE14 simeprevir 2014-05-14 2014-01-30 
Incivo J05AP02 telaprevir 2011-09-19 2011-11-08 
Victrelis J05AP03 boceprevir 2011-07-18 2011-11-08 
Sovaldi§ J05AX15 sofosbuvir 2014-01-16 2014-01-24 
Jevtana L01CD04 cabazitaxel 2011-03-17 2010-12-29 
Yervoy§ L01XC11 ipilimumab 2011-07-13 2010-08-19 
Adcetris L01XC12 brentuximab vedotin 2012-10-25 2012-06-20 
Perjeta L01XC13 pertuzumab 2013-03-04 2013-01-15 
Kadcyla L01XC14 trastuzumab emtansine 2013-11-15 2013-06-17 
Opdivo§ L01XC17 nivolumab 2015-06-19 2015-05-06 
Keytruda§ L01XC18 pembrolizumab 2015-07-17 2015-01-21 
Cyramza L01XC21 ramucirumab 2014-12-19 2014-07-02 
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Medicinal 
product 
ATC code Common name EMA date* Prioritization 
date# 
Zelboraf§ L01XE15 vemurafenib 2012-02-17 2012-02-02 
Xalkori L01XE16 crizotinib 2012-10-23 2012-04-13 
Jakavi L01XE18 ruxolitinib 2012-08-23 2012-06-25 
Stivarga L01XE21 regorafenib 2013-08-26 2013-03-18 
Masiviera L01XE22 masitinib R2014-05-22 2013-07-03 
Tafinlar L01XE23 dabrafenib 2013-08-26 2013-06-11 
Mekinist L01XE25 trametinib 2014-06-30 2013-12-11 
Imbruvica§ L01XE27 ibrutinib 2014-10-21 2014-08-28 
Vargatef L01XE31 nintedanib 2014-11-21 2014-09-10 
Ofev L01XE31 nintedanib 2015-01-15 2015-04-07 
Tekinex L01XX40 omacetaxine mepesuccinate  W2011-01-11 2011-04-27 
Erivedge L01XX43 vismodegib 2013-07-12 2013-01-03 
Zaltrap L01XX44 aflibercept 2013-02-01 2012-09-25 
Kyprolis§ L01XX45 carfilzomib 2015-11-19 2015-10-07 
Lynparza L01XX46 olaparib 2014-12-16 2014-05-07 
Imlygic L01XX51 talimogene laherparepvec 2015-12-16 2015-05-11 
Xtandi§ L02BB04 enzalutamide 2013-06-21 2013-01-29 
Zytiga§ L02BX03 abiraterone 2011-09-05 2011-10-18 
Lympreva L03AX dasiprotimut-t R2015-07-03 2015-03-12 
Benlysta L04AA26 belimumab 2011-07-13 2011-06-01 
Gilenya§ L04AA27 fingolimod 2011-03-17 2010-12-22 
Nulojix L04AA28 belatacept 2011-06-17 2011-05-24 
Aubagio L04AA31 teriflunomide 2013-08-26 2012-10-22 
Otezla§ L04AA32 apremilast 2015-01-15 2014-12-09 
Entyvio§ L04AA33 vedolizumab 2014-05-22 2014-02-20 
Lemtrada L04AA34 alemtuzumab 2013-09-12 2013-04-10 
Movectro L04AA40 cladribine W2011-02-08 2010-12-22 
Cosentyx§ L04AC10 secukinumab 2015-01-15 2014-12-09 
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Medicinal 
product 
ATC code Common name EMA date* Prioritization 
date# 
Prolia M05BX04 denosumab 2010-05-26 2010-04-29 
Xiapex M09AB02 collagenase Clostridium 
histolyticum 
2011-02-28 2010-12-06 
Translarna M09AX03 ataluren 2014-07-31 2013-12-18 
Fampyra N07XX07 fampridine 2011-07-20 2011-05-24 
Vyndaqel N07XX08 tafamidis 2011-11-16 2011-10-31 
Tecfidera§ N07XX09 dimethyl fumarate 2014-01-30 2013-02-15 
Nerventra N07XX10 laquinimod R2014-08-19 2013-07-03 
Anoro R03AL03 umeclidinium 
bromide/vilanterol 
2014-05-08 2014-02-09 
Daxas R03DX07 roflumilast 2010-07-05 2010-09-15 
Nucala R03DX09 mepolizumab 2015-12-02 2015-04-22 
Kalydeco R07AX02 ivacaftor 2012-07-23 2012-07-26 
Orkambi R07AX30 lumacaftor/ivacaftor 2015-11-19 2015-06-09 
Eylea§ S01LA05 aflibercept 2012-11-22 2012-05-18 
Praxbind V03AB37 idarucizumab 2015-11-20 2015-10-13 
Xofigo V10XX03 radium Ra223 dichloride 2013-11-13 2013-03-26 
Qsiva — phentermine/topiramate R2013-05-14 2011-10-18 
ATC anatomical therapeutic chemical classification system 
* EMA marketing authorization date, or EMA refusal date, or date of withdrawal of the initial marketing 
authorization application 
# Prioritization made by the Swedish Horizon Scanning System; date of early assessment report 
publication 
§ Medicinal product with sales > €4 million in the second year on the market 
W Withdrawal of marketing authorization application 
R Refusal of marketing authorization application 
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Table 4. Medicines not prioritized by the Swedish Horizon Scanning System 
Medicinal 
product§ 
ATC code Common name EMA date* 
Elocta B02BD02 efmoroctocog alfa 2015-11-19 
Opsumit C02KX04 macitentan 2013-12-20 
Triumeq J05AR13 abacavir sulfate/dolutegravir sodium/lamivudine 2014-09-01 
Daklinza J05AX14 daclatasvir 2014-08-22 
Harvoni J05AX65 ledipasvir/sofosbuvir  2014-11-17 
ATC anatomical therapeutic chemical classification system 
§ Medicinal products with sales > €4 million in the second year on the market 
* EMA marketing authorization date 
A breakdown of the study population by prioritization status and economic impact as 
well as the calculated sensitivity, specificity, positive predictive value, and negative 
predictive value are provided in Figure 9. 
 
Figure 9. Tabulation by prioritization status and economic impact 
Economic impact*
HS System
Prioritized
Not 
prioritized
> €4 million ≤ €4 million
16 55
5 177
Sensitivity
[95% CI]
76.2%
[52.8–91.8]
Specificity
[95% CI]
76.3%
[70.3–81.6]
PPV
[95% CI]
22.5%
[13.5–34.0]
NPV
[95% CI]
97.3%
[93.7–99.1]
CI confidence interval HS horizon scanning NPV negative predictive value  
PPV positive predictive value

* In the second year on the market

  29 
4.2 STUDY II 
In Study I it was observed that the Swedish Horizon Scanning System prioritized nine 
new medicines intended for use in patients with multiple sclerosis. Two of these—
fampridine (Fampyra) and cannabinoids (Sativex)—were treatments limited to the 
management of symptoms. The other seven medicines were disease-modifying 
treatments: fingolimod (Gilenya), cladribine (Movectro), teriflunomide (Aubagio), 
dimethyl fumarate (Tecfidera), alemtuzumab (Lemtrada), laquinimod (Nerventra), and 
daclizumab (Zinbryta). While the original marketing authorization application for 
cladribine was withdrawn, in 2017 the medicine was eventually granted marketing 
authorization by EMA under the brand name Mavenclad. The marketing authorization 
application for laquinimod, however, was refused by EMA due to an unfavorable 
benefit–risk assessment. 
Two additional disease-modifying treatments used in multiple sclerosis were not 
prioritized by the Swedish Horizon Scanning System. During the study period off-
label use of rituximab in multiple sclerosis patients increased steadily. Also, in 2014, 
peginterferon beta-1a (Plegridy) was granted marketing authorization by EMA. 
Utilization trends of multiple sclerosis disease-modifying treatments are presented in 
Figure 10. There was a limited uptake of alemtuzumab, teriflunomide, peginterferon 
beta-1a, and daclizumab—neither accounted for more than 5% of disease-modifying 
treatment use in multiple sclerosis patients in any given month. Therefore, these 
products were not included as interventions in the interrupted time series analyses. 
The analyses showed that reimbursement of fingolimod and reimbursement of 
dimethyl fumarate were both associated with changes in utilization patterns of other 
disease-modifying treatments. 
The local recommendation on rituximab was associated with increasing use of 
rituximab. The regional drug and therapeutics committee recommendation on 
dimethyl fumarate had no direct effect on its use. However, shortly after the 
recommendation a clear downward trend in dimethyl fumarate use was observed. 
Additional analyses based on monthly sales data were also conducted to describe 
dimethyl fumarate utilization trends in the three largest regions in Sweden. Sales per 
1000 population were calculated to account for differences in population size (Figure 
11). While rapid uptake was observed in all three regions, the utilization trends 
diverged following the month of the treatment recommendation issued in Region 
Stockholm. 
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Figure 10. Number of prevalent multiple sclerosis disease-modifying treatment users 
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Figure 11. Sales of dimethyl fumarate in the three largest regions 
4.3 STUDY III 
Dimethyl fumarate—the first oral disease-modifying treatment approved as a first-line 
treatment option for relapsing-remitting multiple sclerosis patients—was the subject 
of Study III. The study provided the opportunity to look into the use of real-world 
data in a disease area with a number of medicines administered exclusively in the 
hospital setting. 
On 15 February 2013 dimethyl fumarate was prioritized by the Swedish Horizon 
Scanning System. The marketing authorization application was approved by EMA on 
30 January 2014. Only three months later dimethyl fumarate was included by the TLV 
in the pharmaceutical benefits scheme and made available for broad use in relapsing-
remitting multiple sclerosis patients. Region Stockholm included dimethyl fumarate in 
the managed introduction process. There was no recorded use of dimethyl fumarate in 
the region prior to the TLV decision date (9 May 2014). 
Dimethyl fumarate had a rapid market uptake both at the regional and national level in 
Sweden. Nationally, during the first three years on the market, total sales amounted to 
SEK 413 million (Figure 12). As per the definition used in Study I, the medicine was 
classified as having substantial economic impact on the healthcare system. In its 
second year on the Swedish market it was the highest grossing medicinal product 
behind only the new hepatitis C medicines. 
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The month of the regional DTC recommendation on how dimethyl fumarate should be
used in Region Stockholm is indicated by the vertical bar
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Figure 12. Sales of dimethyl fumarate 
 
Figure 13. Dimethyl fumarate initiation patterns 
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A majority of patients had been treated with other disease-modifying treatments prior 
to initiating treatment with dimethyl fumarate. Initiation patterns of dimethyl fumarate 
are illustrated in Figure 13. 
During the study period 425 patients initiated treatment with dimethyl fumarate in 
Region Stockholm. Study selection criteria were met by 400 patients (Figure 14). 
Baseline characteristics are presented below and in Figure 15. 
 
Figure 14. Characteristics of patients initiating dimethyl fumarate 
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Figure 15. Use of medicines and healthcare resource utilization in patients treated with dimethyl 
fumarate 
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Treatment persistence estimates are plotted in Figure 16. The probability of staying on 
treatment with dimethyl fumarate at two years was 46% among treatment-naïve 
patients and 40% among those who had previously been treated with another disease-
modifying treatment. 
 
Figure 16. Persistence with dimethyl fumarate 
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4.4 STUDY IV 
Targeted cancer medicine olaparib—the first approved poly(adenosine diphosphate–
ribose) polymerase (PARP) inhibitor—was the subject of Study IV. In this study 
national-level data were used to assess the real-world use and outcomes of olaparib. 
Olaparib was prioritized on 7 May 2014 by the Swedish Horizon Scanning System, 
and approved on 14 December 2014 by EMA for use in ovarian cancer. Less than 
three months later, on 25 February 2015, it was included by the TLV in the 
pharmaceutical benefits scheme. This product was also included in the national 
process for the managed introduction of new medicines. The time between the 
marketing authorization approval by EMA and the first use by patients in Sweden was 
only two months. There was no record of use of olaparib prior to its inclusion in the 
pharmaceutical benefits scheme. 
During the first three years on the market in Sweden, over 100 patients were treated 
with olaparib with sales amounting to SEK 46 million (Figure 17). While olaparib was 
not classified as having substantial economic impact based on the definition used in 
Study I, the Swedish Horizon Scanning System had prioritized the medicine as it was 
judged to be an innovative approach to treatment of ovarian cancer. 
 
Figure 17. National sales of olaparib 
Characteristics of patients who were dispensed olaparib are presented in Figure 18. 
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Figure 18. Characteristics of ovarian cancer patients initiating olaparib 
Fifty-seven patients discontinued olaparib during the follow-up period. Median time to 
olaparib discontinuation was 9.5 months (Figure 19) and median overall survival was 
33.0 months (Figure 20). 
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Figure 19. Time to treatment discontinuation in ovarian cancer patients treated with olaparib 
 
Figure 20. Overall survival in ovarian cancer patients treated with olaparib 
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5 DISCUSSION 
In the pursuit of the important aim of improving patient outcomes and experience of 
care while managing constrained budgets, payers and providers seek to enable 
appropriate and sustainable access to new medicines. Various policy options exist to 
help facilitate this. For example, a recent report by the Organisation for Economic 
Cooperation and Development (OECD) listed horizon scanning, use of measures to 
encourage rational prescribing, as well as assessment of medicines in routine clinical 
practice among possible policy options that healthcare systems may adopt to facilitate 
rational use of new medicines [45]. Such initiatives, however, should be informed by 
research and be subject to continuous evaluation [118]. 
This thesis examined selected elements of the process for managed introduction of 
new medicines that have been used in Sweden for at least a decade. This chapter 
discusses the evaluation of the horizon scanning system, the impact of treatment 
recommendations, and the utility of regional and national data sources for the 
assessment of new specialist medicines in routine clinical practice. 
5.1 EVALUATION OF HORIZON SCANNING 
Horizon scanning activities have been carried out in Sweden since the mid-2000s. 
Since then the horizon scanning process has evolved and adapted to meet the needs of 
its customers with considerable knowledge and skills acquired along the way. 
It was warranted, therefore, to share a detailed description of the Swedish Horizon 
Scanning System with wider audiences, both in Sweden and internationally. Upon 
reviewing publicly accessible information on horizon scanning work conducted in 
other countries [119–125] and completing the review on the evolution of horizon 
scanning in Sweden it became clear that there are many similarities across systems [53]. 
This is not surprising for at least two reasons. First, at its inception the Swedish 
Horizon Scanning System was advised and supported by the United Kingdom’s 
National Institute for Health Research (NIHR) Horizon Scanning Research and 
Intelligence Centre (HSC) [53]. The NIHR HSC was also among the founder 
members of the EuroScan International Network and played a pivotal role in defining 
and developing horizon scanning methods [119, 126–130]. Second, once established, 
the Swedish Horizon Scanning Working Group, in its turn, shared experiences with 
stakeholders from other countries, including Denmark, Belgium, the Netherlands, 
Luxembourg, and Austria [131]. 
Given that the Swedish Horizon Scanning System may be viewed as an exemplar 
internationally [41] and that it has a clear influencing role in the national process for 
managed introduction of new medicines [53], an evaluation of its performance was 
necessary. The selection of a study design for the evaluation was informed by a 
comprehensive literature review.  
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While many horizon scanning systems have been described in the literature, only four 
evaluations were identified. These were the evaluations of the NIHR HSC [105, 132], 
the Austrian Horizon Scanning Programme [133], and the United States Agency for 
Healthcare Research and Quality (AHRQ) Healthcare Horizon Scanning System [134]. 
The Austrian Horizon Scanning Programme was assessed in a qualitative study 
comprising a survey, a download analysis, an environmental analysis, and an online 
questionnaire to evaluate user satisfaction [133]. Quantitative methods have also been 
used in the evaluation of horizon scanning activities. The accuracy of prioritization 
made by the NIHR HSC was assessed twice based on an approach used in diagnostic 
test accuracy studies [105, 132]. Finally, the AHRQ Healthcare Horizon Scanning 
System was evaluated using both qualitative and quantitative methods that were similar 
to those used in the evaluations of the Austrian and the NIHR HSC systems [134]. In 
addition, the EuroScan Methods Toolkit [135] and a published evaluation framework 
[126] provided valuable insights for the development of the study design for the 
Swedish evaluation. Upon reviewing available options, it was decided to focus on 
assessing the accuracy of the system. 
A number of specific features of the Swedish Horizon Scanning System had to be 
accounted for in the design of the study. Among them, the broad range of 
prioritization criteria used in the filtration and prioritization steps posed a challenge. 
The decision to prioritize a new medicine is binary—a medicine is either prioritized or 
not. The assessment of the accuracy of prioritization therefore required a binary 
reference classification of all new medicines. As a reference standard, national sales 
data were used to classify new medicines according to their economic impact. 
Narrowing down the assessment to the accuracy of the prioritization of new 
medicines with substantial economic impact not only provided a feasible approach to 
quantitatively assess the entire output of the Swedish Horizon Scanning System but 
also addressed the important question of whether payers were informed of such 
impactful medicines ahead of their launch. The pros and cons of using sales data as a 
reference standard have been discussed in the publication [136]. It should also be 
noted that this evaluation approach allowed for a quantitative and reproducible 
assessment of both inpatient and outpatient medicines across all therapeutic areas. 
The assessment of the accuracy of the Swedish Horizon Scanning System showed that 
all new medicines processed by EMA were identified. Of these 253 new medicines, 71 
were prioritized and 21 were classified as having substantial economic impact based on 
the reference standard. Of these 21 medicines, five were not prioritized. However, as 
discussed in the publication, these medicines were identified by the system but not 
selected for early assessment because similar medicines had already been prioritized or 
marketed [136]. Among the medicinal products classified as having substantial 
economic impact, almost all were specialist medicines. New cancer medicines 
comprised over one third of these. Overall, many new cancer medicines also had an 
orphan designation. Moreover, the analyses of sales data showed that, outside of the 
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new medicines for hepatitis C, dimethyl fumarate, the utilization of which was 
explored in depth in Study III, was the highest grossing new medicine in Sweden.  
In addition to the assessment of accuracy, other aspects of the Swedish Horizon 
Scanning System may also warrant evaluation. The EuroScan Methods Toolkit 
suggests that evaluations should be thought of as a progressive activity taking place in 
several dimensions [135]. Aspects that could be explored include user satisfaction and 
the use of the outputs for decision making. Moreover, gaining insights on how the 
filtration and prioritization criteria are applied may help to identify alternative 
approaches to defining a reference standard for use in future accuracy assessments. In 
addition, a comprehensive review of the content and impact of early assessment 
reports may further contribute to a better understanding of the overall effectiveness of 
the system. 
It is expected that horizon scanning in Sweden will continue to evolve as a response to 
both health innovation and policy initiatives. For example, the scope of the Swedish 
Horizon Scanning System could be expanded to identify other health technologies 
such as medical devices and diagnostics [137–139]. Furthermore, identification of 
disinvestment opportunities could also help payers and providers to optimize the 
provision of healthcare services [140]. Moreover, as healthcare systems move toward 
patient and person-centeredness it may be warranted to facilitate patient and public 
involvement in horizon scanning activities [141]. Finally, providing support to cross-
national collaborations, including the ongoing health technology assessment initiatives 
EUnetHTA [142], FINOSE [143], and BeNeLuxA [144], may also bring benefits 
[145]. 
5.2 IMPACT OF TREATMENT RECOMMENDATIONS 
The treatment recommendations issued by the regional drug and therapeutics 
committees have become a well-established tool for facilitating rational use of both 
new and established medicines [146]. Specialists in hospitals may also issue local 
recommendations focusing on steering the use of medicines within their clinics. 
Moreover, within the national process for managed introduction of new medicines, 
the New Therapies Council can develop national treatment recommendations, 
typically on specialist medicines, to facilitate rational and equitable use across the 
regions.  
The regional drug and therapeutics committees initially focused on facilitating rational 
use of established medicines, particularly those prescribed in primary care [63, 68, 
147]. It has, however, been recognized that evidence-based treatment 
recommendations can also enable rational introduction of new medicines [66]. For 
example, as part of the model for managed introduction of new medicines in Region 
Stockholm, treatment recommendations have been used to steer the prescribing of 
weight loss medicines [148–150] and oral anticoagulants [67], both largely prescribed 
by general practitioners [150, 151]. It has however been shown that different factors 
may drive the adoption of new medicines across healthcare settings [152] and that 
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general practitioners and specialists may vary in their response to treatment 
recommendations [153, 154]. Given that a considerable share of new medicines is 
intended for use in the specialized care setting, research into the impact of treatment 
recommendations on specialist prescribing was warranted. 
As was seen in Study I, several new medicines were introduced for the treatment of 
relapsing-remitting multiple sclerosis. To help steer the use of these medicines, 
treatment recommendations were issued at the local and regional level. The availability 
of continuously recorded individual-level data on inpatient and outpatient use of 
disease-modifying treatments in all multiple sclerosis patients residing in the region 
provided an opportunity to assess the impact of these recommendations using an 
interrupted time series design. An alternative analytical approach to the one used could 
have been a comparative interrupted time series design [155] that would have included 
a control series from another region in which no specific activities were undertaken to 
steer the prescribing of rituximab and dimethyl fumarate. However, it was not possible 
to obtain a complete overview of the utilization of disease-modifying treatments in 
other regions because data on inpatient use of medicines were not readily available in 
databases at the national level. Nonetheless, national monthly sales data on dimethyl 
fumarate were used to describe trends in the three largest regions in Sweden. These 
descriptive analyses demonstrated that dimethyl fumarate use in Region Stockholm 
was the lowest with noticeable differences emerging following the treatment 
recommendation. The impact of the recommendations as well as strengths and 
limitations of the analyses are discussed further in the publication [156]. 
Among the recently introduced multiple sclerosis medicines, only fingolimod and 
dimethyl fumarate impacted the utilization of disease-modifying treatments. Notably, 
in Study I, fingolimod and dimethyl fumarate were classified as requiring prioritization. 
The alignment of these findings lends support to the utility of using sales data as a 
reference standard for assessing horizon scanning accuracy. Rituximab, repurposed for 
the treatment of multiple sclerosis, was however not prioritized by the Swedish 
Horizon Scanning System even though scanning for new indications of existing 
medicines is within its scope. This can be explained, however, by the fact that no 
marketing authorization application for the use of rituximab in this indication had 
been submitted. 
In addition to the assessment of treatment recommendations in multiple sclerosis 
conducted as part of this thesis, two other recent studies also explored the impact of 
treatment recommendations on the use of new medicines in Sweden. Treatment 
recommendations issued as part of the regional managed introduction of non-vitamin 
K antagonist oral anticoagulants were found to be influential in the choice of 
anticoagulants prescribed [67]. At the national level, it was shown that prescribers 
adhered to the recommendations on the use of new direct-acting antivirals for 
treatment of hepatitis C [70]. In summary, these findings indicate that evidence-based 
treatment recommendations can support the rational introduction and use of new 
medicines, including those used in the specialized care setting. 
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5.3 ASSESSMENT OF THE USE AND OUTCOMES OF NEW MEDICINES 
USING HEALTHCARE DATABASES 
Routine clinical care in Sweden generates real-world data that for decades have been 
used to inform decision making [157–166]. The establishment of the Prescribed Drug 
Register enabled nation-wide observational research on the use and outcomes of 
prescribed medicines [101, 167, 168]. In addition, some of the new medicines used in 
hospitals have been recorded in patient registries [169, 170]. Historically, most 
observational research was conducted by academics and clinicians. Payers and 
providers have also been increasingly making use of available data to support decision 
making [37, 66, 171, 172]. The interest in leveraging real-world data continues to grow 
and new uses are being explored by various stakeholders. 
Assessment of the use and outcomes of new medicines is an important part of the 
process for managed introduction [51, 53]. Among the new medicines prioritized by 
the Swedish Horizon Scanning System, dimethyl fumarate and olaparib were included 
as pilots in the managed introduction process. Studies III and IV explored the utility 
of existing healthcare databases for addressing questions about the real-world use and 
outcomes of specialist medicines using dimethyl fumarate and olaparib as examples.  
Studies III and IV therefore fulfilled two purposes. First, these studies described the 
use and assessed the outcomes of treatment with dimethyl fumarate and olaparib. 
Second, the studies highlighted both opportunities and challenges of using healthcare 
databases for conducting studies on new medicines used in the specialized care setting. 
A thorough discussion of the uptake, utilization, and outcomes of treatment with 
dimethyl fumarate in relapsing-remitting multiple sclerosis patients and with olaparib 
in ovarian cancer patients is provided in the publications [173, 174]. Moreover, the 
publications include a discussion on differences between the observations from 
routine care and the results of the pivotal clinical trials and also cover study-specific 
strengths and limitations. 
Given the scope of this thesis, the remainder of this section focuses on the utility of 
existing healthcare databases for supporting the process for managed introduction of 
new medicines in Sweden.  
At the outset of a research project initiated to support decision making it is of critical 
importance to define the research question. A well-defined research question is 
necessary to guide subsequent decisions around study design and data needs. At the 
time of the introduction of a new medicine, there is a need to assess whether it is used 
appropriately, with the definition of “appropriate” being context-dependent, and also 
to gain an understanding of the medicine’s value in routine clinical practice. Some 
questions can be answered with existing healthcare databases, while others may require 
primary data collection. 
Dimethyl fumarate was the first oral disease-modifying treatment approved for use as 
a first-line option in relapsing-remitting multiple sclerosis patients. Other first-line 
treatment alternatives available at the time of its introduction were injectable 
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treatments (interferon betas and glatiramer acetate). While more expensive than the 
other treatments, dimethyl fumarate was perceived to be more effective. However, 
there were also concerns about the relatively high dropout rates reported in the clinical 
trials. Therefore, it was considered necessary to monitor the uptake and to assess 
persistence with dimethyl fumarate in routine clinical practice. 
The decision to use the existing healthcare databases of Region Stockholm was 
supported by earlier research that had validated the use of procedure codes to identify 
multiple sclerosis disease-modifying treatments administered in hospitals [175]. By 
combining the hospital data with data on medicines dispensed in pharmacies it was 
possible to provide a complete description of the utilization of all disease-modifying 
treatments at the individual level. This allowed to assert the line of treatment in which 
dimethyl fumarate was used. Moreover, it provided more accurate estimates of 
treatment persistence, given that switching to medicines administered in hospitals was 
common. This type of population-based research opportunity is however rare [176]. 
Olaparib was the first PARP inhibitor to be approved for treatment of ovarian cancer. 
The Swedish Horizon Scanning System prioritized olaparib as an innovative treatment 
[136]. Among many new cancer medicines, olaparib was subsequently included as the 
first cancer medicine to go through the national process for managed introduction and 
follow-up. Given the national scope of this project, the existing national population-
based registers were chosen as the data source. Disease registries may also contain 
useful data; such data sources should be explored in future studies. 
The Prescribed Drug Register provided data on all dispensed packages of olaparib, 
free-text documentation on directions for use, and the use of concomitant medicines 
to manage side effects. Because data on medicines administered in hospitals are 
generally not available in the population-based registers, monthly sales data were 
reviewed to estimate the use of olaparib in the hospital setting. The national Cancer 
Register, which includes records on all new cancer cases, provided information on the 
tumor site, histological type, and stage. Importantly, these data allowed for the 
identification of off-label use of olaparib. Finally, access to up-to-date death records 
enabled robust estimation of overall survival [103], something that internationally is 
generally not possible [177]. 
Several common challenges were encountered in the assessment of both dimethyl 
fumarate and olaparib. These include a lack of data on the use of medicines in 
hospitals, limited recording of clinical data, and reliance on the accuracy and 
completeness of the available information. 
While opportunities exist for the documentation of medicines administered in 
hospitals, these medicines are currently not captured consistently at the individual 
level. Hence, in light of the evidentiary needs to monitor the utilization, effectiveness, 
safety, and value of new medicines, many of which increasingly are administered in the 
hospital setting, there is a need to facilitate systematic recording of these medicines 
across hospitals and therapeutic areas.  
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Limited access to clinical data makes it difficult to assess whether the use of medicines 
can be judged as appropriate and to study relevant outcomes. Examples of relevant 
data that were either not readily available or of inconsistent quality include reasons for 
treatment discontinuation, findings from medical imaging and genetic testing, and 
evaluations of disease status and progression. Data from electronic health records, that 
have been implemented nationally since 2012, have the potential to fill some of these 
data gaps. However, the use of electronic health records for research requires 
functions to ensure accuracy and completeness of the collected data [75]. 
Furthermore, the use of different electronic health record systems and fragmented 
access can impact usability of the data.  
It should always be kept in mind that any observational study based on secondary data 
will be dependent on the accuracy and completeness of the data used. Validity of data 
should thus be regularly assessed given that it can be influenced by many factors and 
can change over time. 
Moreover, as seen in this thesis, new specialist medicines—particularly orphan 
medicines and medicines with narrow indications or restricted reimbursement—are 
used in relatively small patient populations. This may pose methodological challenges 
in assessing the value of these new medicines in routine clinical practice. Also, the 
findings indicate that the very first patients receiving a new medicine in routine clinical 
practice may differ considerably from the patients in the pivotal trials. For example, 
the first wave of dimethyl fumarate uptake was predominantly due to patients 
switching from other disease-modifying treatments. While a detailed description of the 
first olaparib users could not be provided it is possible that they also differed from the 
trial participants. Finally, when it comes to the assessment of treatment outcomes, a 
balance needs to be found between allowing for sufficient follow-up time to accrue 
and providing timely insights to decision makers. If analyses are performed too soon 
after the introduction then data may not be mature yet. However, if done too late then 
an opportunity to improve patient outcomes may be missed. 
Despite the aforementioned limitations, data collected as part of routine care in 
Sweden provide unique research opportunities. All persons residing in Sweden have 
access to healthcare from birth or immigration until death or emigration. Moreover, 
the existence of a personal identity number assigned to every resident allows for 
linkage of data across various data sources. This enables a broad range of assessments 
of the use of new medicines and associated outcomes in routine clinical practice.  
Acknowledging that the research opportunities in Sweden are unique, it is perhaps not 
surprising that the complete population-based overview of drug utilization in multiple 
sclerosis is the only one of its kind published to date. Similarly, almost five years after 
the marketing authorization of olaparib, the research presented here provides the only 
published evidence on the use and outcomes of olaparib in routine clinical practice. 
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6 CONCLUSIONS 
This thesis examined selected elements of the process for managed introduction of 
new medicines. A complete description and evaluation of the Swedish Horizon 
Scanning System was performed. This was followed by an assessment of the utility of 
regional and national data sources in examining the uptake, use, and outcomes of 
prioritized medicines in key therapeutic areas. Moreover, the impact of treatment 
recommendations as a tool to facilitate rational use of new medicines was assessed. 
The conclusions of this thesis are presented below. 
/ Regional and national decision makers can rely on the outputs of the  
Swedish Horizon Scanning System to keep informed about new medicines.  
The assessment demonstrated that all new medicines were identified and all 
innovative medicines that went on to have substantial economic impact  
were assessed prior to their introduction. 
/ Assessment of drug utilization in multiple sclerosis was possible because  
individual-level data on the use of both inpatient and outpatient medicines  
were recorded in the regional data. 
/ Assessment of use and outcomes of the growing number of new specialist 
medicines, including new cancer treatments, may be impeded by a lack of  
fit-for-purpose data. 
/ Treatment recommendations can influence the uptake and utilization of  
new medicines used in the specialized care setting. 
 

  49 
7 ACKNOWLEDGEMENTS 
I owe special thanks to Björn Wettermark who made it possible to get this project 
going. I do appreciate your commitment and unwavering support. Also, I would like 
to thank David Collins who spoke with me about the importance of finding the fit 
when I first contemplated the idea of pursuing a doctoral degree. Moreover, I must 
say that I would have probably never got into the field of drug utilization research and 
pharmacoepidemiology if not for Silvia Alessi-Severini and Keith Simons who in 
essence enabled my research career. 
Rickard Malmström and Brian Godman helped shape this project from the beginning. 
Our discussions about new medicines were indispensable. 
Mia von Euler joined as a supervisor and became a trusted friend. Your contributions 
are too numerous to list here and I appreciate everything you have done for me. 
Also, I am fortunate to be a mentee of Anders Ekbom—you do understand me and I 
cannot thank you enough for your endorsement. 
It was a joy to work together with Fredrik Piehl and Kjell Bergfeldt, who contributed 
with clinical expertise in neurology and oncology, respectively. A generalist like myself 
relies on collaborations with clinicians—I am grateful to Fredrik and Kjell for their 
investment in these studies. 
The evaluation of the Swedish Horizon Scanning System was greatly facilitated by 
Anna Bergkvist Christensen, Marie Persson, Morgan Edström, Anna Lindhé, and 
Helena Ramström. I would also like to thank Thomas Cars and Joris Komen for 
providing timely support with data analyses. 
I appreciate that Tomas Salmonson, Anders Viberg, Freddi Lewin, and Jan Liliemark 
provided feedback on my manuscripts. I am grateful to Håkan Holmberg and Caroline 
Gredenborn for advice on the Swedish national registers. 
I must also thank my colleagues at Region Stockholm and Karolinska Institutet—in 
particular Kristina Aggefors, Sofie Alverlind, Morten Andersen, Pernilla Appelquist, 
Elizabeth Arkema, Lisen Arnheim Dahlström, Johan Askling, Pia Bastholm Rahmner, 
Gustaf Befrits, Ulf Bergman, Lena Brandt, Erica Brostedt, Gustaf Bruze, Margit 
Budai, Elin Dahlén, Michael Fored, Tomas Forslund, Thomas Frisell, Pia Frisk, Per 
Haglund, Maria Juhasz Haverinen, Linnéa Karlsson, Helle Kieler, Gerd Lärfars, 
Birgitta Lilja, Marie Linder, Love Linnér, Gunnar Ljunggren, Desirée Loikas, Sven-
Åke Lööv, Göran Lord, Lillemor Melander, Mahan Nikpour Ardaly, Helena Nord, 
Björn Pasternak, Andreas Pettersson, Miriam Qvarnström, Petra Rinnetorp, Sten 
Ronge, Monica Rundgren, Diana Rydberg, Pia Sandelius, Jonas Söderling, Magnus 
Thyberg, Ulrika Undén, Carl Willers, and Eva Willis—for the support provided. 
Finally, I appreciate that Region Stockholm and the Swedish Association of Local 
Authorities and Regions funded this research. 

  51 
8 REFERENCES 
1. Kesselheim A, Wang B, Avorn J (2013) Defining “innovativeness” in drug 
development: a systematic review. Clin Pharmacol Ther 94:336–348. 
https://doi.org/10.1038/clpt.2013.115 
2. Kesselheim AS, Avorn J (2013) The most transformative drugs of the past 25 years: 
a survey of physicians. Nat Rev Drug Discov 12:nrd3977. 
https://doi.org/10.1038/nrd3977  
3. Ward DJ, Slade A, Genus T, et al (2014) How innovative are new drugs launched in 
the UK? A retrospective study of new drugs listed in the British National Formulary 
(BNF) 2001–2012. BMJ Open 4:e006235. https://doi.org/10.1136/bmjopen-2014-
006235  
4. Naci H, Carter AW, Mossialos E (2015) Why the drug development pipeline is not 
delivering better medicines. BMJ Br Medical J 351:h5542. 
https://doi.org/10.1136/bmj.h5542  
5. Schuhmacher A, Gassmann O, Hinder M (2016) Changing R&D models in 
research-based pharmaceutical companies. J Transl Med 14:105. 
https://doi.org/10.1186/s12967-016-0838-4  
6. Hill R, Rang H (eds) (2013) Drug discovery and development. Churchill 
Livingstone. https://doi.org/10.1016/c2009-0-54235-3 
7. Stevens JL, Baker TK (2009) The future of drug safety testing: expanding the view 
and narrowing the focus. Drug Discov Today 14:162–167. 
https://doi.org/10.1016/j.drudis.2008.11.009  
8. Dixit R, Iciek LA, McKeever K, Ryan P (2009) Challenges of general safety 
evaluations of biologics compared to small molecule pharmaceuticals in animal 
models. Expert Opin Drug Dis 5:79–94. 
https://doi.org/10.1517/17460440903443410  
9. Langhof H, Chin W, Wieschowski S, et al (2018) Preclinical efficacy in therapeutic 
area guidelines from the U.S. Food and Drug Administration and the European 
Medicines Agency: a cross-sectional study. Brit J Pharmacol 175:4229–4238. 
https://doi.org/10.1111/bph.14485  
10. Shen J, Swift B, Mamelok R, et al (2019) Design and conduct considerations for 
first-in-human trials. Clin Transl Sci 12:6–19. https://doi.org/10.1111/cts.12582  
11. Corr PB, Williams DA (2009) The pathway from idea to regulatory approval: 
examples for drug development. In: Lo B, Field MJ (eds) Conflict of interest in 
medical research, education, and practice. The National Academies Press, Washington, 
DC, p375–383 
 52 
12. Karakunnel JJ, Bui N, Palaniappan L, et al (2018) Reviewing the role of healthy 
volunteer studies in drug development. J Transl Med 16:336. 
https://doi.org/10.1186/s12967-018-1710-5  
13. Turner RJ (2010) New drug development. Springer, New York, NY 
14. Rosier JA, Martens MA, Thomas JR (2014) Global new drug development. John 
Wiley & Sons, Ltd 
15. Zhang X, Zhang Y, Ye X, et al (2016) Overview of phase IV clinical trials for 
postmarket drug safety surveillance: a status report from the ClinicalTrials.gov registry. 
BMJ Open 6:e010643. https://doi.org/10.1136/bmjopen-2015-010643  
16. Kesselheim AS, Myers JA, Avorn J (2011) Characteristics of clinical trials to 
support approval of orphan vs nonorphan drugs for cancer. JAMA 305:2320–2326. 
https://doi.org/10.1001/jama.2011.769  
17. Downing NS, Aminawung JA, Shah ND, et al (2014) Clinical trial evidence 
supporting FDA approval of novel therapeutic agents, 2005-2012. JAMA 311:368–
377. https://doi.org/10.1001/jama.2013.282034  
18. Wang B, Kesselheim AS (2015) Characteristics of efficacy evidence supporting 
approval of supplemental indications for prescription drugs in United States, 2005-14: 
systematic review. BMJ Br Medical J 351:h4679. https://doi.org/10.1136/bmj.h4679  
19. Hatswell AJ, Baio G, Berlin JA, et al (2016) Regulatory approval of 
pharmaceuticals without a randomised controlled study: analysis of EMA and FDA 
approvals 1999–2014. BMJ Open 6:e011666. https://doi.org/10.1136/bmjopen-2016-
011666  
20. Goring S, Taylor A, Müller K, et al (2019) Characteristics of non-randomised 
studies using comparisons with external controls submitted for regulatory approval in 
the USA and Europe: a systematic review. BMJ Open 9:e024895. 
https://doi.org/10.1136/bmjopen-2018-024895  
21. Swedish Medical Products Agency (2019) www.lakemedelsverket.se  
22. European Medicines Agency (2019) www.ema.europa.eu  
23. Baird L, Banken R, Eichler H, et al (2014) Accelerated access to innovative 
medicines for patients in need. Clin Pharmacol Ther 96:559–571. 
https://doi.org/10.1038/clpt.2014.145  
24. Eichler H, Baird L, Barker R, et al (2015) From adaptive licensing to adaptive 
pathways: delivering a flexible life-span approach to bring new drugs to patients. Clin 
Pharmacol Ther 97:234–246. https://doi.org/10.1002/cpt.59  
25. Eichler H-G, Barker R, Bedlington N, et al (2018) The evolution of adaptiveness: 
balancing speed and evidence. Nat Rev Drug Discov 17:845. 
https://doi.org/10.1038/nrd.2018.90  
  53 
26. Anell A, Glenngård AH, Merkur S (2012) Sweden health system review. Heal Syst 
Transition 14:1–159  
27. Anell A (2015) The public–private pendulum—patient choice and equity in 
Sweden. New Engl J Medicine 372:1–4. https://doi.org/10.1056/nejmp1411430  
28. Dental and Pharmaceutical Benefits Agency (2019) www.tlv.se  
29. Dental and Pharmaceutical Benefits Agency (2017) PPRI Pharma Profile Sweden 
2017 
30. Drews J (2000) Drug discovery: a historical perspective. Science 287:1960–1964. 
https://doi.org/10.1126/science.287.5460.1960  
31. Mullins DC, Montgomery R, Tunis S (2010) Uncertainty in assessing value of 
oncology treatments. Oncol 15:58–64. https://doi.org/10.1634/theoncologist.2010-
s1-58  
32. Nicod E, Brigham K, Durand-Zaleski I, Kanavos P (2017) Dealing with 
uncertainty and accounting for social value judgments in assessments of orphan drugs: 
evidence from four European countries. Value Health 20:919–926. 
https://doi.org/10.1016/j.jval.2017.03.005  
33. Towse A, Mauskopf JA (2018) Affordability of new technologies: the next frontier. 
Value Health 21:249–251. https://doi.org/10.1016/j.jval.2018.01.011  
34. Danzon PM (2018) Affordability challenges to value-based pricing: mass diseases, 
orphan diseases, and cures. Value Health 21:252–257. 
https://doi.org/10.1016/j.jval.2017.12.018  
35. Schaffer S, Messner D, Mestre-Ferrandiz J, et al (2018) Paying for cures: 
perspectives on solutions to the “affordability issue.” Value Health 21:276–279. 
https://doi.org/10.1016/j.jval.2017.12.013  
36. Flume M, Bardou M, Capri S, et al (2018) Approaches to manage ‘affordability’ of 
high budget impact medicines in key EU countries. J Mark Access Heal Policy 
6:1478539. https://doi.org/10.1080/20016689.2018.1478539  
37. Wettermark B, Persson ME, Wilking N, et al (2010) Forecasting drug utilization 
and expenditure in a metropolitan health region. BMC Health Serv Res 10:128. 
https://doi.org/10.1186/1472-6963-10-128  
38. Godman B, Malmström RE, Diogene E, et al (2014) Dabigatran – a continuing 
exemplar case history demonstrating the need for comprehensive models to optimize 
the utilization of new drugs. Frontiers in pharmacology 5:109. 
https://doi.org/10.3389/fphar.2014.00109  
39. Godman B, Malmström RE, Diogene E, et al (2014) Are new models needed to 
optimize the utilization of new medicines to sustain healthcare systems? Expert Rev 
Clin Phar 8:77–94. https://doi.org/10.1586/17512433.2015.990380  
 54 
40. Bonanno P, Ermisch M, Godman B, et al (2017) Adaptive pathways: possible next 
steps for payers in preparation for their potential implementation. Frontiers in 
pharmacology 8:497. https://doi.org/10.3389/fphar.2017.00497  
41. Godman B, Bucsics A, Bonanno P, et al (2018) Barriers for access to new 
medicines: searching for the balance between rising costs and limited budgets. 
Frontiers Public Heal 6:328. https://doi.org/10.3389/fpubh.2018.00328  
42. World Health Organization Regional Office for Europe (2015) Access to new 
medicines in Europe: technical review of policy initiatives and opportunities for 
collaboration and research 
43. The United Nations Secretary-General’s High-Level Panel on Access to Medicines 
(2016) Promoting innovation and access to health technologies 
44. Panteli D, Edwards S (2018) Ensuring access to medicines: how to stimulate 
innovation to meet patients’ needs? European Observatory on Health Systems and 
Policies 
45. Organisation for Economic Co-operation and Development (2018) 
Pharmaceutical innovation and access to medicines. 
https://doi.org/10.1787/9789264307391-en 
46. Boivin A, L’Espérance A, Gauvin F, et al (2018) Patient and public engagement in 
research and health system decision making: a systematic review of evaluation tools. 
Health Expect 21:1075–1084. https://doi.org/10.1111/hex.12804  
47. Kayser L, Karnoe A, Duminski E, et al (2019) A new understanding of health 
related empowerment in the context of an active and healthy ageing. BMC Health Serv 
Res 19:242. https://doi.org/10.1186/s12913-019-4082-5  
48. Evén G, Spaak J, von Arbin M, et al (2019) Health care professionals’ experiences 
and enactment of person-centered care at a multidisciplinary outpatient specialty clinic. 
J Multidiscip Healthc 12:137–148. https://doi.org/10.2147/jmdh.s186388  
49. Bengtsson T, Scott K (2011) Population aging and the future of the welfare state: 
the example of Sweden. Popul Dev Rev 37:158–170. https://doi.org/10.1111/j.1728-
4457.2011.00382.x  
50. Davey A, Malmberg B, Sundström G (2014) Aging in Sweden: local variation, local 
control. Gerontologist 54:525–532. https://doi.org/10.1093/geront/gnt124  
51. Gustafsson LL, Wettermark B, Kalin M, et al (2008) A model for structured 
introduction of new drugs. Läkartidningen 105:2917–22  
52. Godman B, Wettermark B, Hoffmann M, et al (2009) Multifaceted national and 
regional drug reforms and initiatives in ambulatory care in Sweden: global relevance. 
Expert review of pharmacoeconomics & outcomes research 9:65–83. 
https://doi.org/10.1586/14737167.9.1.65  
  55 
53. Eriksson I, Wettermark B, Persson M, et al (2017) The Early Awareness and Alert 
System in Sweden: history and current status. Front Pharmacol 8:674. 
https://doi.org/10.3389/fphar.2017.00674  
54. Swedish Medical Products Agency (2017). The national pharmaceutical strategy 
2017. Available at www.lakemedelsverket.se/overgripande/Om-
Lakemedelsverket/Nationell-lakemedelsstrategi 
55. Region Stockholm (2019). Janusinfo. www.janusinfo.se 
56. HTAi-INAHTA (2019). The health technology assessment glossary: horizon 
scanning. Available at www.htaglossary.net 
57. Field MJ, Lohr KN (eds) (1990) Institute of Medicine. Clinical practice guidelines: 
directions for a new program. National Academies Press, Washington DC 
58. Woolf SH (1990) Practice guidelines: a new reality in medicine: I. recent 
developments. Arch Intern Med 150:1811–1818. 
https://doi.org/10.1001/archinte.1990.00390200025005  
59. Eichelbaum M, Dahl M-L, Sjöqvist F (2018) Clinical pharmacology in Stockholm 
50 years—report from the jubilee symposium. Eur J Clin Pharmacol 74:843–851. 
https://doi.org/10.1007/s00228-018-2432-6  
60. Sjoqvist F, Bergman U, Dahl M-L, et al (2002) Drug and therapeutics committees: 
a Swedish experience. WHO Drug Information 16:207  
61. Wettermark B, Godman B, Andersson K, et al (2008) Recent national and regional 
drug reforms in Sweden. Pharmacoeconomics 26:537–550. 
https://doi.org/10.2165/00019053-200826070-00001  
62. Bergström G, Karlberg I (2007) Decentralized responsibility for costs of 
outpatient prescription pharmaceuticals in Sweden: assessment of models for 
decentralized financing of subsidies from a management perspective. Health Policy 
81:358–367. https://doi.org/10.1016/j.healthpol.2006.07.006  
63. Gustafsson LL, Wettermark B, Godman B, et al (2011) The ‘Wise List’– a 
comprehensive concept to select, communicate and achieve adherence to 
recommendations of essential drugs in ambulatory care in Stockholm. Basic Clin 
Pharmacol 108:224–233. https://doi.org/10.1111/j.1742-7843.2011.00682.x  
64. Jägestedt M, Ronge S, Wettermark B, Karlsson E (2008) Rationell 
läkemedelsförskrivning: en kunskaps- och linjefråga. Läkartidningen 105:2924–29  
65. Wettermark B, Pehrsson A, Juhasz-Haverinen M, et al (2009) Financial incentives 
linked to self-assessment of prescribing patterns: a new approach for quality 
improvement of drug prescribing in primary care. Quality in primary care 17:179–89  
66. Eriksen J, Gustafsson LL, Ateva K, et al (2017) High adherence to the ‘Wise List’ 
treatment recommendations in Stockholm: a 15-year retrospective review of a 
 56 
multifaceted approach promoting rational use of medicines. BMJ Open 7:e014345. 
https://doi.org/10.1136/bmjopen-2016-014345  
67. Komen J, Forslund T, Hjemdahl P, et al (2017) Effects of policy interventions on 
the introduction of novel oral anticoagulants in Stockholm: an interrupted time series 
analysis. Brit J Clin Pharmaco 83:642–652. https://doi.org/10.1111/bcp.13150  
68. Eriksen J, Ovesjö M-L, Vallin M, et al (2018) Primary care physicians report high 
trust in and usefulness of the Stockholm drug and therapeutic committee’s list of 
recommended essential medicines (the ‘Wise List’). Eur J Clin Pharmacol 74:131–138. 
https://doi.org/10.1007/s00228-017-2354-8  
69. National Board of Health and Welfare (2019) www.socialstyrelsen.se  
70. Frisk P, Aggefors K, Cars T, et al (2018) Introduction of the second-generation 
direct-acting antivirals (DAAs) in chronic hepatitis C: a register-based study in 
Sweden. Eur J Clin Pharmacol 74:971–978. https://doi.org/10.1007/s00228-018-
2456-y  
71. Lund JL, Richardson DB, Stürmer T (2015) The active comparator, new user study 
design in pharmacoepidemiology: historical foundations and contemporary 
application. Curr Epidemiology Reports 2:221–228. https://doi.org/10.1007/s40471-
015-0053-5  
72. Sherman RE, Anderson SA, Pan GJ, et al (2016) Real-world evidence—what is it 
and what can it tell us? New Engl J Medicine 375:2293–2297. 
https://doi.org/10.1056/nejmsb1609216  
73. Makady A, de Boer A, Hillege H, et al (2017) What is real-world data? A review of 
definitions based on literature and stakeholder interviews. Value Health 20:858–865. 
https://doi.org/10.1016/j.jval.2017.03.008  
74. U.S. Food and Administration (2018) Framework for FDA’s real-world evidence 
program 
75. Eriksson I, Ibanez L (2016) Secondary data sources for drug utilization research. 
In: Elseviers M et al (eds) Drug Utilization Research. John Wiley Sons, Ltd, New 
Jersey 
76. Furu K, Wettermark B, Andersen M, et al (2010) The Nordic countries as a cohort 
for pharmacoepidemiological research. Basic Clin Pharmacol 106:86–94. 
https://doi.org/10.1111/j.1742-7843.2009.00494.x  
77. Berger ML, Sox H, Willke RJ, et al (2017) Good practices for real-world data 
studies of treatment and/or comparative effectiveness: recommendations from the 
joint ISPOR–ISPE special task force on real-world evidence in health care decision 
making. Value Health 20:1003–1008. https://doi.org/10.1016/j.jval.2017.08.3019  
  57 
78. Schneeweiss S, Eichler H, Garcia-Altes A, et al (2016) Real world data in adaptive 
biomedical innovation: a framework for generating evidence fit for decision-making. 
Clin Pharmacol Ther 100:633–646. https://doi.org/10.1002/cpt.512  
79. Sherman RE, Davies KM, Robb MA, et al (2017) Accelerating development of 
scientific evidence for medical products within the existing US regulatory framework. 
Nat Rev Drug Discov 16:297–298. https://doi.org/10.1038/nrd.2017.25  
80. Fralick M, Kesselheim AS, Avorn J, Schneeweiss S (2017) Use of health care 
databases to support supplemental indications of approved medications. JAMA Intern 
Med 178:55. https://doi.org/10.1001/jamainternmed.2017.3919  
81. Franklin JM, Glynn RJ, Martin D, Schneeweiss S (2019) Evaluating the use of 
nonrandomized real-world data analyses for regulatory decision making. Clin 
Pharmacol Ther 105:867–877. https://doi.org/10.1002/cpt.1351  
82. Ferrario A, Kanavos P (2015) Dealing with uncertainty and high prices of new 
medicines: a comparative analysis of the use of managed entry agreements in Belgium, 
England, the Netherlands and Sweden. Soc Sci Med 124:39–47. 
https://doi.org/10.1016/j.socscimed.2014.11.003  
83. Makady A, ten Ham R, de Boer A, et al (2017) Policies for use of real-world data in 
health technology assessment (HTA): a comparative study of six HTA agencies. Value 
Health 20:520–532. https://doi.org/10.1016/j.jval.2016.12.003  
84. Makady A, van Veelen A, Jonsson P, et al (2018) Using real-world data in health 
technology assessment (HTA) practice: a comparative study of five HTA agencies. 
Pharmacoeconomics 36:359–368. https://doi.org/10.1007/s40273-017-0596-z  
85. Hurwitz JT, Brown M, Graff JS, et al (2017) Is real-world evidence used in P&T 
monographs and therapeutic class reviews? J Manag Care Spec Ph 23:613–620. 
https://doi.org/10.18553/jmcp.2017.16368  
86. Hampson G, Towse A, Dreitlein WB, et al (2018) Real-world evidence for 
coverage decisions: opportunities and challenges. J Comp Effect Res 7:1133–1143. 
https://doi.org/10.2217/cer-2018-0066  
87. Pearson SD, Dreitlein WB, Towse A, et al (2018) A framework to guide the 
optimal development and use of real-world evidence for drug coverage and formulary 
decisions. J Comp Effect Res 7:1145–1152. https://doi.org/10.2217/cer-2018-0059  
88. Malone DC, Brown M, Hurwitz JT, et al (2018) Real-world evidence: useful in the 
real world of US payer decision making? How? When? And what studies? Value 
Health 21:326–333. https://doi.org/10.1016/j.jval.2017.08.3013  
89. Avorn J (2013) The promise of pharmacoepidemiology in helping clinicians assess 
drug risk. Circulation 128:745–748. 
https://doi.org/10.1161/circulationaha.113.003419  
 58 
90. Ball R, Robb M, Anderson S, Pan DG (2016) The FDA’s sentinel initiative—a 
comprehensive approach to medical product surveillance. Clin Pharmacol Ther 
99:265–268. https://doi.org/10.1002/cpt.320  
91. Schneeweiss S, Gagne J, Glynn R, et al (2011) Assessing the comparative 
effectiveness of newly marketed medications: methodological challenges and 
implications for drug development. Clin Pharmacol Ther 90:777–790. 
https://doi.org/10.1038/clpt.2011.235  
92. Schneeweiss S (2019) Real-world evidence of treatment effects: the useful and the 
misleading. Clin Pharmacol Ther 106:43–44. https://doi.org/10.1002/cpt.1405  
93. Swedish eHealth Agency (2019) www.ehalsomyndigheten.se  
94. Region Stockholm (2019) GUPS. Available at 
www.vardgivarguiden.se/avtaluppdrag/it-stod-och-e-tjanster/e-tjanster-och-system-a-
o/ekonomi-och-uppfoljning/uppfoljningsportalen-gups/  
95. Region Stockholm (2019) Hälso- och sjukvårdsnämndens årsredovisning för 
verksamhetsåret 2018  
96. Region Stockholm (2019) www.sll.se  
97. SAS Institute Inc. (2019) Möjlighet att följa en individ genom hela vårdförloppet, 
avidientifierad. Available at www.sas.com/sv_se/customers/stockholm-lans-
landsting-vard-databas.html  
98. Statistics Sweden (2019) www.scb.se  
99. Ludvigsson JF, Almqvist C, Bonamy A-K, et al (2016) Registers of the Swedish 
total population and their use in medical research. European Journal of Epidemiology 
31:125–136. https://doi.org/10.1007/s10654-016-0117-y  
100. Doidge JC, Harron K (2017) Demystifying probabilistic linkage. Int J Popul Data 
Sci 3:. https://doi.org/10.23889/ijpds.v3i1.410  
101. Wettermark B, Hammar N, MichaelFored C, et al (2007) The new Swedish 
Prescribed Drug Register—opportunities for pharmacoepidemiological research and 
experience from the first six months. Pharmacoepidem Dr S 16:726–735. 
https://doi.org/10.1002/pds.1294  
102. Barlow L, Westergren K, Holmberg L, Talbäck M (2009) The completeness of 
the Swedish Cancer Register – a sample survey for year 1998. Acta Oncologica 48:27–
33. https://doi.org/10.1080/02841860802247664  
103. Brooke H, Talbäck M, Hörnblad J, et al (2017) The Swedish cause of death 
register. Eur J Epidemiol 32:765–773. https://doi.org/10.1007/s10654-017-0316-1  
  59 
104. Knottnerus J., Muris J. (2003) Assessment of the accuracy of diagnostic tests: the 
cross-sectional study. J Clin Epidemiol 56:1118–1128. 
https://doi.org/10.1016/s0895-4356(03)00206-3  
105. Simpson S, Hyde C, Cook A, et al (2004) Assessing the accuracy of forecasting: 
Applying standard diagnostic assessment tools to a health technology early warning 
system. Int J Technol Assess 20:381–384. 
https://doi.org/10.1017/s0266462304001229  
106. Wagner A, Soumerai S, Zhang F, Ross-Degnan D (2002) Segmented regression 
analysis of interrupted time series studies in medication use research. J Clin Pharm 
Ther 27:299–309. https://doi.org/10.1046/j.1365-2710.2002.00430.x  
107. Altman D, Bland J (1994) Statistics notes: diagnostic tests 1: sensitivity and 
specificity. BMJ 308:1552. https://doi.org/10.1136/bmj.308.6943.1552  
108. Altman DG, Bland MJ (1994) Statistics notes: diagnostic tests 2: predictive values. 
BMJ 309:102. https://doi.org/10.1136/bmj.309.6947.102  
109. Durbin J, Watson G (1951) Testing for serial correlation in least squares 
regression. II. Biometrika 38:159. https://doi.org/10.2307/2332325  
110. Box GE, Jenkins GM (1976) Time series analysis: forecasting and control. 
Holden-Day 
111. McDowall D, McCleary R, Meidinger E, Hay RA (1980) Interrupted time series 
analysis. SAGE Publications, Inc 
112. Altman DG, Bland M (1998) Time to event (survival) data. BMJ. 
https://doi.org/10.1136/bmj.317.7156.468  
113. Swedish Ethical Review Authority (2018) www.etikprovning.se  
114. Rognehaugh R (2001) The health information technology dictionary. Aspen 
Publishers  
115. Gostin LO, Levit LA, Nass SJ (2009) Beyond the HIPAA privacy rule: enhancing 
privacy, improving health through research. National Academies Press  
116. Turn R, Ware WH (1976) Privacy and security issues in information systems. The 
RAND Corporation  
117. Ludvigsson J, Nørgaard M, Weiderpass E, et al (2015) Ethical aspects of registry-
based research in the Nordic countries. Clin Epidemiology Volume 7:491–508. 
https://doi.org/10.2147/clep.s90589  
118. Brownson RC, Chriqui JF, Stamatakis KA (2009) Understanding evidence-based 
public health policy. Am J Public Health 99:1576–1583. 
https://doi.org/10.2105/ajph.2008.156224  
 60 
119. Stevens A, Packer C, Robert G (1998) Early warning of new health care 
technologies in the United Kingdom. Int J Technol Assess 14:680–686. 
https://doi.org/10.1017/s0266462300011995  
120. Mundy L, Merlin TL, Parrella A, et al (2005) The Australia and New Zealand 
Horizon Scanning Network. Aust Health Rev 29:395–397. 
https://doi.org/10.1071/ah050395  
121. Nachtnebel A, Geiger-Gritsch S, Hintringer K, Wild C (2012) Scanning the 
horizon—development and implementation of an early awareness system for 
anticancer drugs in Austria. Health Policy 104:1–11. 
https://doi.org/10.1016/j.healthpol.2011.11.003  
122. Morrison A (2012) Scanning the horizon in a decentralized healthcare system: the 
Canadian experience. Int J Technol Assess 28:327–332. 
https://doi.org/10.1017/s0266462312000323  
123. Packer C, Simpson S, de Almeida R (2015) EuroScan international network 
member agencies: their structure, processes, and outputs. Int J Technol Assess 31:78–
85. https://doi.org/10.1017/s0266462315000100  
124. Grössmann N, Wolf S, Rosian K, Wild C (2019) Pre-reimbursement: early 
assessment for coverage decisions. Wien Med Wochenschr 1–9. 
https://doi.org/10.1007/s10354-019-0683-1  
125. Marangi M, Ivanovic J, Pistritto G (2019) The horizon scanning system at the 
Italian Medicines Agency. Drug Discov Today. 
https://doi.org/10.1016/j.drudis.2019.04.010  
126. Murphy K, Packer C, Stevens A, Simpson S (2007) Effective early warning 
systems for new and emerging health technologies: developing an evaluation 
framework and an assessment of current systems. Int J Technol Assess 23:324–330. 
https://doi.org/10.1017/s0266462307070493  
127. Simpson S, Packer C, Carlsson P, et al (2008) Early identification and assessment 
of new and emerging health technologies: actions, progress, and the future direction of 
an international collaboration—EuroScan. Int J Technol Assess 24:518–525. 
https://doi.org/10.1017/s0266462308080689  
128. Smith J, Cook A, Packer C (2010) Evaluation criteria to assess the value of 
identification sources for horizon scanning. Int J Technol Assess 26:348–353. 
https://doi.org/10.1017/s026646231000036x  
129. Fung M, Simpson S, Packer C (2011) Identification of innovation in public 
health. J Public Health 33:123–130. https://doi.org/10.1093/pubmed/fdq045  
130. Packer C, Gutierrez-Ibarluzea I, Simpson S (2012) The evolution of early 
awareness and alert methods and systems. Int J Technol Assess 28:199–200. 
https://doi.org/10.1017/s0266462312000426  
  61 
131. Lepage-Nefkens I, Douw K, Mantjes G, et al (2017) Horizon scanning for 
pharmaceuticals: proposal for the BeNeLuxA collaboration  
132. Packer C, Fung M, Stevens A (2012) Analyzing 10 years of early awareness and 
alert activity in the United Kingdom. Int J Technol Assess 28:308–314. 
https://doi.org/10.1017/s026646231200030x  
133. Nachtnebel A, Breuer J, Willenbacher W, et al (2016) Looking back on 5 years of 
horizon scanning in oncology. Int J Technol Assess 32:54–60. 
https://doi.org/10.1017/s0266462316000052  
134. Duda N, Fleming C, Kirwin K, et al (2016) Evaluation of the AHRQ Healthcare 
Horizon Scanning System. Mathematica Policy Research  
135. EuroScan International Network (2014) A toolkit for the identification and 
assessment of new and emerging health technologies  
136. Eriksson I, von Euler M, Malmström RE, et al (2019) Did we see it coming? An 
evaluation of the Swedish Early Awareness and Alert System. Appl Heal Econ Heal 
Policy 17:93–101. https://doi.org/10.1007/s40258-018-0434-2  
137. Packer C, Boddice B, Simpson S (2013) Regenerative medicine techniques in 
cardiovascular disease: where is the horizon? Regen Med 8:351–360. 
https://doi.org/10.2217/rme.13.21  
138. Smith J, Ward D, Michaelides M, et al (2015) New and emerging technologies for 
the treatment of inherited retinal diseases: a horizon scanning review. Eye 29:1131–
1140. https://doi.org/10.1038/eye.2015.115  
139. Farrah K, Mierzwinski-Urban M (2019) Almost half of references in reports on 
new and emerging nondrug health technologies are grey literature. J Med Libr Assoc 
107:43–48. https://doi.org/10.5195/jmla.2019.539  
140. Polisena J, Trunk G, Gutierrez-Ibarluzea I, Joppi R (2019) Disinvestment 
activities and candidates in the health technology assessment community: an online 
survey. Int J Technol Assess 35:189–194. 
https://doi.org/10.1017/s0266462319000229  
141. Simpson S, Cook A, Miles K (2018) Patient and public involvement in early 
awareness and alert activities: an example from the United Kingdom. Int J Technol 
Assess 34:10–17. https://doi.org/10.1017/s0266462317004421  
142. European Network for Health Technology Assessment [EUnetHTA] (2019) 
www.eunethta.eu 
143. Dental and Pharmaceutical Benefits Agency (2017) FINOSE, a Nordic 
cooperation. www.tlv.se/in-english/international-collaboration/finose---a-nordic-
cooperation.html 
144. The BeNeLuxA Initiative on Pharmaceutical Policy (2019) www.beneluxa.org  
 62 
145. Vogler S, Paris V, Panteli D (2018) Ensuring access to medicines: how to 
redesign pricing, reimbursement and procurement?  
146. Björkhem-Bergman L, Andersén-Karlsson E, Laing R, et al (2013) Interface 
management of pharmacotherapy. Joint hospital and primary care drug 
recommendations. Eur J Clin Pharmacol 69:73–78. https://doi.org/10.1007/s00228-
013-1497-5  
147. Aelsson M, Spetz M, Mellén A, Wallerstedt SM (2008) Use of and attitudes 
towards the prescribing guidelines booklet in primary health care doctors. BMC Clin 
Pharmacol 8:8. https://doi.org/10.1186/1472-6904-8-8  
148. Wettermark B, Raaschou P, Forslund T, Hjemdahl P (2007) Still questions 
around the slimming agent rimobant. Not approved in USA because of the risk of 
mental adverse effects. Läkartidningen 104:3879  
149. Forslund T, Wettermark B, Raaschou P, et al (2010) Anti-obesity agents do not 
seem to have any beneficial effects. Health centers prescribe preparations haphazardly, 
according to a medical records study. Läkartidningen 107:910  
150. Forslund T, Raaschou P, Hjemdahl P, et al (2011) Usage, risk, and benefit of 
weight-loss drugs in primary care. J Obes 2011:459263. 
https://doi.org/10.1155/2011/459263  
151. Komen J, Forslund T, Hjemdahl P, Wettermark B (2017) Factors associated with 
antithrombotic treatment decisions for stroke prevention in atrial fibrillation in the 
Stockholm region after the introduction of NOACs. Eur J Clin Pharmacol 73:1315–
1322. https://doi.org/10.1007/s00228-017-2289-0  
152. Lublóy Á (2014) Factors affecting the uptake of new medicines: a systematic 
literature review. BMC Health Serv Res 14:469. https://doi.org/10.1186/1472-6963-
14-469  
153. Mason A (2008) New medicines in primary care: a review of influences on 
general practitioner prescribing. J Clin Pharm Ther 33:1–10. 
https://doi.org/10.1111/j.1365-2710.2008.00875.x  
154. Chauhan D, Mason A (2008) Factors affecting the uptake of new medicines in 
secondary care – a literature review. J Clin Pharm Ther 33:339–348. 
https://doi.org/10.1111/j.1365-2710.2008.00925.x  
155. Bernal J, Cummins S, Gasparrini A (2018) The use of controls in interrupted time 
series studies of public health interventions. Int J Epidemiol 47:2082–2093. 
https://doi.org/10.1093/ije/dyy135  
156. Eriksson I, Komen J, Piehl F, et al (2018) The changing multiple sclerosis 
treatment landscape: impact of new drugs and treatment recommendations. Eur J Clin 
Pharmacol 74:663–670. https://doi.org/10.1007/s00228-018-2429-1  
  63 
157. Bergman U, Elmes P, Halse M, et al (1975) The measurement of drug 
consumption. European journal of clinical pharmacology 8:83--89  
158. Bergman U, Boman G, Wiholm B-E (1978) Epidemiology of adverse drug 
reactions to phenformin and metformin. Br Med J 2:464--466  
159. Bergman U, Sjoqvist F (1984) Measurement of drug utilization in Sweden: 
methodological and clinical implications. Acta Medica Scandinavica 215:15--22  
160. Ekbom A, Helmick C, Zack M, Adami H-O (1990) Ulcerative Colitis and 
Colorectal Cancer. New Engl J Medicine 323:1228–1233. 
https://doi.org/10.1056/nejm199011013231802  
161. Isacsson G, Boëthius G, Bergman U (1992) Low level of antidepressant 
prescription for people who later commit suicide: 15 years of experience from a 
population-based drug database in Sweden. Acta Psychiat Scand 85:444–448. 
https://doi.org/10.1111/j.1600-0447.1992.tb03209.x  
162. Blomqvist P, Ekbom A, Carlsson P, et al (1997) Benign prostatic hyperplasia in 
Sweden 1987 to 1994: changing patterns of treatment, changing patterns of costs. 
Urology 50:214–220  
163. Blomqvist P, Feltelius N, Ekbom A, Klareskog L (2000) Rheumatoid arthritis in 
Sweden. Drug prescriptions, costs, and adverse drug reactions. J Rheumatology 
27:1171–7  
164. Blomqvist P, Feltelius N, Löfberg R, Ekbom A (2001) A 10-year survey of 
inflammatory bowel diseases—drug therapy, costs and adverse reactions. Aliment 
Pharm Therap 15:475–481. https://doi.org/10.1046/j.1365-2036.2001.00942.x  
165. Wettermark B, Nyman K, Bergman U (2004) Five years’ experience of quality 
assurance and feedback with individual prescribing profiles at a primary healthcare 
centre in Stockholm, Sweden. Quality in Primary Care 12:225--234  
166. Blomqvist P, Ekbom A (2009) Inflammatory bowel diseases: health care and 
costs in Sweden in 1994. Scand J Gastroentero 32:1134–1139. 
https://doi.org/10.3109/00365529709002993  
167. Wettermark B, Zoëga H, Furu K, et al (2013) The Nordic prescription databases 
as a resource for pharmacoepidemiological research—a literature review. 
Pharmacoepidem Dr S 22:691–699. https://doi.org/10.1002/pds.3457  
168. Wallerstedt SM, Wettermark B, Hoffmann M (2016) The first decade with the 
Swedish Prescribed Drug Register – a systematic review of the output in the scientific 
literature. Basic Clin Pharmacol 119:464–469. https://doi.org/10.1111/bcpt.12613  
169. Askling J, Fored C, Geborek P, et al (2006) Swedish registers to examine drug 
safety and clinical issues in RA. Ann Rheum Dis 65:707. 
https://doi.org/10.1136/ard.2005.045872  
 64 
170. Holmén C, Piehl F, Hillert J, et al (2010) A Swedish national post-marketing 
surveillance study of natalizumab treatment in multiple sclerosis. Mult Scler J 17:708–
719. https://doi.org/10.1177/1352458510394701  
171. Wettermark B, Bergman U, Krakau I (2006) Using aggregate data on dispensed 
drugs to evaluate the quality of prescribing in urban primary health care in Sweden. 
Public Health 120:451–461. https://doi.org/10.1016/j.puhe.2005.10.011  
172. Cars T, Eriksson I, Granath A, et al (2017) Antibiotic use and bacterial 
complications following upper respiratory tract infections: a population-based study. 
BMJ open 7:e016221. https://doi.org/10.1136/bmjopen-2017-016221  
173. Eriksson I, Cars T, Piehl F, et al (2018) Persistence with dimethyl fumarate in 
relapsing-remitting multiple sclerosis: a population-based cohort study. Eur J Clin 
Pharmacol 74:219–226. https://doi.org/10.1007/s00228-017-2366-4  
174. Eriksson I, Wettermark B, Bergfeldt K (2018) Real-world use and outcomes of 
olaparib: a population-based cohort study. Target Oncol 13:725–733. 
https://doi.org/10.1007/s11523-018-0604-z  
175. Swedish Association of Local Authorities and Regions (2014) Individdata om 
rekvisitionsläkemedel 2014  
176. Larsen MD, Cars T, Hallas J (2013) A minireview of the use of hospital-based 
databases in observational inpatient studies of drugs. Basic Clin Pharmacol 112:13–18. 
https://doi.org/10.1111/j.1742-7843.2012.00928.x  
177. Gingery D (2018) Real-world evidence challenges: death among toughest data 
points to measure. Pink Sheet  
 
 
   
APPENDIX 
 
 
